[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 342
1. Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, Chow WH: GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev; 2007;31(3):233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas.
  • BACKGROUND: Polymorphisms in glutathione-S-transferase (GST), N-acetyltransferase (NAT) 1, and CYP1A1 genes have been suggested as susceptibility factors for esophageal and gastric adenocarcinomas, but have not been consistently linked to elevated risks.
  • Population controls from the same catchment areas were frequency matched to expected age and sex distributions of esophageal and gastric cardia adenocarcinomas.
  • DNA was extracted from buffy coat for PCR-based assays, with interpretable genotyping results obtained from 209 controls, 67 esophageal adenocarcinomas, 60 gastric cardia adenocarcinomas, and 56 noncardia gastric adenocarcinomas.
  • The respective ORs for esophageal, cardia, and other gastric adenocarcinomas were 1.73 (0.75-4.02), 1.46 (0.57-3.73), and 1.22 (0.48-3.09).
  • CONCLUSIONS: Additional research in larger samples is needed to further assess polymorphisms and their interactions with epidemiologic risk factors, particularly for esophageal adenocarcinoma, which has been increasing markedly in incidence.
  • [MeSH-major] Adenocarcinoma / genetics. Arylamine N-Acetyltransferase / genetics. Cytochrome P-450 CYP1A1 / genetics. Esophageal Neoplasms / genetics. Glutathione Transferase / genetics. Isoenzymes / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2004;39(3):220-30 [15064998.001]
  • [Cites] DNA Cell Biol. 1990 Apr;9(3):193-203 [2340091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(22):8923-7 [2247466.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] PCR Methods Appl. 1995 Jun;4(6):357-62 [7580930.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5226-9 [7585580.001]
  • [Cites] Pharmacogenetics. 1996 Apr;6(2):187-91 [9156696.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1013-8 [9829710.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):586-9 [9973204.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3389-93 [15526353.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):3-28 [10667460.001]
  • [Cites] Pharmacogenetics. 2001 Nov;11(8):655-61 [11692073.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48 [11751440.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] World J Gastroenterol. 2002 Feb;8(1):49-53 [11833070.001]
  • [Cites] J Gastrointest Surg. 2002 May-Jun;6(3):359-67 [12022988.001]
  • [Cites] Int J Cancer. 2002 Jul 20;100(3):249-60 [12115538.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):95-102 [12406553.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Neurosci Lett. 2003 Jan 30;337(1):5-8 [12524158.001]
  • [Cites] Cancer Detect Prev. 2003;27(2):139-46 [12670526.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):384-6 [12692115.001]
  • (PMID = 17646057.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057983-03; United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057983; United States / Intramural NIH HHS / / Z99 DA999999; United States / NCI NIH HHS / CA / U01 CA057923; United States / NIEHS NIH HHS / ES / P30 ES007033; United States / NCI NIH HHS / CP / N01 CP040501; United States / NIEHS NIH HHS / ES / P30 ES010126-07; United States / NCI NIH HHS / CP / N01 CP040501-09; United States / NCI NIH HHS / CP / N01CP040501-009; United States / NCI NIH HHS / CN / N01 CN005230; United States / NIEHS NIH HHS / ES / P30 ES007033-13
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  • [Other-IDs] NLM/ NIHMS29977; NLM/ PMC2268246
  •  go-up   go-down


2. Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT: Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol; 2009 Nov 21;15(43):5465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection.
  • RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups.
  • CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Carcinoma, Squamous Cell / microbiology. Cardia / microbiology. Esophageal Neoplasms / microbiology. Helicobacter Infections / blood. Helicobacter Infections / complications. Helicobacter pylori / immunology. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2008 Oct;38(10):760-5 [18837801.001]
  • [Cites] Gut. 2008 Jun;57(6):727-33 [17895354.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):226-33 [11158192.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):202-10 [11515678.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):658-60 [11531247.001]
  • [Cites] J Gastroenterol. 2002;37 Suppl 13:28-33 [12109662.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):68-76 [12559187.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):123-8 [12593607.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):129-34 [12593608.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1202-4 [14520446.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] Scand J Gastroenterol Suppl. 1995;212:13-8 [8578226.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1442-7 [9136820.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1316-21 [9260797.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1271-6 [9707050.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):520-4 [10404065.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):621-4 [10428200.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):475-82 [15455377.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):588-93 [15743356.001]
  • [Cites] Helicobacter. 2005 Aug;10(4):312-7 [16104947.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1999-2000 [16708392.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2827-31 [17036331.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1188-99 [17383866.001]
  • [Cites] Scand J Gastroenterol. 2007 Aug;42(8):933-40 [17613922.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):387-94 [10685740.001]
  • (PMID = 19916178.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Other-IDs] NLM/ PMC2778104
  •  go-up   go-down


3. Bhurgri Y, Pervez S, Kayani N, Haider S, Ahmed R, Usman A, Bashir I, Bhurgri A, Hasan SH, Zaidi SM: Rising incidence of gastric malignancies in Karachi, 1995- 2002. Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):41-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rising incidence of gastric malignancies in Karachi, 1995- 2002.
  • INTRODUCTION: South Asia is an enigma for gastric cancer, a low risk region with a contradictory high prevalence for Helicobacter pylori.
  • PATIENTS AND METHODS: To examine the demographics, pathology and trends of gastric cancer in Pakistan, epidemiological data of 335 gastric malignancies, registered at Karachi Cancer Registry (KCR) for Karachi South (KS), during 1st January 1995 to 31st December 2002 were reviewed.
  • RESULTS: Ninety six cases of gastric cancers were registered in the 1995-7 period, 61 in males and 35 in females.
  • In the 1998-02 period 239 cases of gastric cancer were registered, 156 cases in males and 83 in females.
  • The majority of the cases presented as poorly or moderately differentiated distal (non-cardia) cancers with a regional spread.
  • CONCLUSION: Gastric cancers in Karachi fall into the prototype of a low risk developing country pattern.
  • Larger pathology-based studies are required to comment on the precise morphological sub-types of gastric adenocarcinoma.
  • Etiological studies focused on different strains of H. pylori are required to address the gastric cancer enigma, whilst examining possible protective environmental or genetic factors.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469622.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


Advertisement
4. Yan L, Yanan D, Donglan S, Na W, Rongmiao Z, Zhifeng C: Polymorphisms of XRCC1 gene and risk of gastric cardiac adenocarcinoma. Dis Esophagus; 2009;22(5):396-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of XRCC1 gene and risk of gastric cardiac adenocarcinoma.
  • This study was designed to investigate the correlation of XRCC1 Arg194Trp Arg280His and Arg399Gln SNPs with the risk of gastric cardiac adenocarcinoma (GCA).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673050.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; 0RH81L854J / Glutamine; 4QD397987E / Histidine; 8DUH1N11BX / Tryptophan; 8J337D1HZY / Cytosine; 94ZLA3W45F / Arginine; JAC85A2161 / Adenine; QR26YLT7LT / Thymine
  •  go-up   go-down


5. Randjelovic T, Filipovic B, Babic D, Cemerikic V, Filipovic B: Carcinosarcoma of the stomach: a case report and review of the literature. World J Gastroenterol; 2007 Nov 7;13(41):5533-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the stomach: a case report and review of the literature.
  • We report the case of a 62-year-old man with gastric carcinosarcoma, along with its clinical, macroscopic and histopathological features.
  • Macroscopically, a specimen of deformed stomach was obtained that measured 200 mm x 150 mm x 100 mm.
  • A 150 mm x 100 mm x 50 mm exophytic tumoral mass (Borrmann type I) was found, which involved the posterior wall from the cardia to the antrum.
  • Histopathologically, a mixed type of malignancy was revealed: an adenocarcinoma with intestinal metaplasia, with interposed fascicles of fusiform atypical cells and numerous large, rounded and oval cells.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinosarcoma / secondary. Liver Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907304.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Chromogranin A; 0 / KRT18 protein, human; 0 / Keratin-18; 0 / Mucin-1; 0 / Vimentin
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC4171295
  •  go-up   go-down


6. Carman S, Kamangar F, Freedman ND, Wright ME, Dawsey SM, Dixon LB, Subar A, Schatzkin A, Abnet CC: Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP Diet and Health Study. Int J Cancer; 2009 Jul 1;125(1):165-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP Diet and Health Study.
  • We investigated the association of dietary alpha-tocopherol, gamma-tocopherol and supplemental vitamin E intake with the risk of esophageal squamous cell carcinoma (n = 158), esophageal adenocarcinoma (n = 382), gastric cardia adenocarcinoma (n = 320) and gastric noncardia adenocarcinoma (GNCA; n = 327) in the NIH-AARP Diet and Health Study, a cohort of approximately 500,000 people.
  • For dietary alpha-tocopherol, we found some evidence of association with decreased esophageal squamous cell carcinoma and increased esophageal adenocarcinoma risk in the continuous analyses, with adjusted hazard ratios and 95% confidence intervals of 0.90 (0.81-0.99) and 1.05 (1.00-1.11), respectively, per 1.17 mg (half the interquartile range) increased intake.
  • There was no association between dietary alpha-tocopherol and gastric cardia adenocarcinoma or GNCA.
  • [MeSH-major] Diet. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology. Tocopherols / administration & dosage
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma, Squamous Cell / epidemiology. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. National Institutes of Health (U.S.). Prospective Studies. Risk Factors. Surveys and Questionnaires. United States / epidemiology. alpha-Tocopherol / administration & dosage. gamma-Tocopherol / administration & dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):133-40 [10861464.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):626-31 [10797282.001]
  • [Cites] Am J Epidemiol. 2000 Aug 1;152(3):279-86 [10933275.001]
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):163-72 [11246845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):35-41 [11815399.001]
  • [Cites] Lancet. 2002 Jul 6;360(9326):23-33 [12114037.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):617-23 [12296509.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • [Cites] Nutr Cancer. 1987;9(2-3):81-92 [3562297.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):896-901 [2335393.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] Int J Cancer. 1994 Jun 1;57(5):638-44 [8194870.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):393-8 [7920206.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):7-12 [9533754.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):601-5 [10521793.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2087-92 [16172214.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):406-15 [16832408.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1128-35 [17548674.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2323-30; quiz 2331 [17581269.001]
  • [Cites] Cancer Causes Control. 2003 Aug;14(6):547-58 [12948286.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1414-6 [13130117.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):444-9 [15297937.001]
  • [Cites] Am J Epidemiol. 1985 Dec;122(6):947-59 [2998182.001]
  • [Cites] Public Health Nutr. 2008 Feb;11(2):183-95 [17610761.001]
  • [Cites] J Nutr. 2003 Mar;133 Suppl 3:933S-940S [12612179.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):575-80 [12384802.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):737-48 [10679641.001]
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):750-4 [10925371.001]
  • (PMID = 19326432.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010196-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-66-2 / Tocopherols; 8EF1Z1238F / gamma-Tocopherol; H4N855PNZ1 / alpha-Tocopherol
  • [Other-IDs] NLM/ NIHMS109107; NLM/ PMC2686122
  •  go-up   go-down


7. Bafandeh Y, Farhang S: Subsite distribution of gastric cancer in an area of high prevalence--northwest Iran. J Epidemiol; 2009;19(4):202-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsite distribution of gastric cancer in an area of high prevalence--northwest Iran.
  • BACKGROUND: The aim of the present study was to determine subsites of gastric cancer in East Azerbaijan, Iran-a high incidence region for gastric cancer and Helicobacter pylori infection.
  • The gastric cardia was involved in 40.3% of patients with gastric adenocarcinoma, while the gastric fundus was involved in 3.7%, the gastric body in 49.1%, and the gastric antrum in 24.1% of patients.
  • Cardia involvement was not associated with the sex or age of patients.
  • CONCLUSIONS: Noncardia gastric cancer is still more frequent in East Azerbaijan, which is likely due to the very high prevalence of infection with Helicobacter pylori.
  • The low rate of cancer involving the fundus is a target for further research on the etiology of gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2008 Apr;17(2):71-6 [18287862.001]
  • [Cites] J Am Coll Surg. 2008 Feb;206(2):306-10 [18222384.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1644-50 [18392661.001]
  • [Cites] Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):327-30 [18712985.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):226-33 [11158192.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):107-13 [11981333.001]
  • [Cites] Gastric Cancer. 2002;5(1):6-15 [12021854.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3522S-3525S [12421881.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):374-7 [8472157.001]
  • [Cites] IARC Sci Publ. 1993;(121):1-806 [8258476.001]
  • [Cites] Gastroenterology. 1995 Dec;109(6):1750-6 [7498638.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400 [9184771.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1169-79 [9609753.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):139-46; discussion 146 [15895452.001]
  • [Cites] Indian J Gastroenterol. 2005 Nov-Dec;24(6):236-8 [16424617.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):683-92 [16388522.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):345-54 [16507831.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):309-12 [16839228.001]
  • [Cites] Nutr Cancer. 2006;54(2):171-8 [16898861.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):480-2 [17059350.001]
  • [Cites] Saudi Med J. 2006 Dec;27(12):1878-81 [17143368.001]
  • [Cites] Arch Iran Med. 2007 Jul;10(3):289-94 [17604463.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Dec;22(12):2242-5 [18031388.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):351-65 [18318820.001]
  • (PMID = 19542688.001).
  • [ISSN] 1349-9092
  • [Journal-full-title] Journal of epidemiology
  • [ISO-abbreviation] J Epidemiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC3924110
  •  go-up   go-down


8. Buckland G, Agudo A, Luján L, Jakszyn P, Bueno-de-Mesquita HB, Palli D, Boeing H, Carneiro F, Krogh V, Sacerdote C, Tumino R, Panico S, Nesi G, Manjer J, Regnér S, Johansson I, Stenling R, Sanchez MJ, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen NE, Key TJ, Bingham S, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Morois S, Boutron-Ruault MC, Trichopoulou A, Lagiou P, Trichopoulos D, Lund E, Couto E, Boffeta P, Jenab M, Riboli E, Romaguera D, Mouw T, González CA: Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr; 2010 Feb;91(2):381-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study.
  • OBJECTIVE: We aimed to explore the association between adherence to a relative Mediterranean diet (rMED) and incident gastric adenocarcinoma (GC) within the European Prospective Investigation into Cancer and Nutrition study.
  • The association between rMED and GC with respect to anatomic location (cardia and noncardia) and histologic types (diffuse and intestinal) was investigated.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20007304.001).
  • [ISSN] 1938-3207
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] ENG
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / 11692; United Kingdom / Medical Research Council / / ; United Kingdom / Department of Health / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Kubo A, Corley DA: Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):872-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis.
  • BACKGROUND: The incidence of esophageal adenocarcinoma has increased markedly in recent decades in many countries.
  • We did a systematic review and statistical synthesis of studies that evaluated the association between body mass index (BMI) and the risk of esophageal adenocarcinoma or the adjacent gastric cardia adenocarcinoma.
  • (b) the occurrence of esophageal or cardia adenocarcinoma diagnosis; and (c) a relative risk or odds ratio (OR) with confidence intervals (CI) or provided sufficient data to permit their calculation.
  • RESULTS: We identified 14 studies (2 cohort, 12 case-control; 2,488 esophageal and 2,509 cardia adenocarcinomas).
  • A high BMI (>25) was associated with an increased risk of esophageal adenocarcinoma (males, OR, 2.2; 95% CI, 1.7-2.7; females, OR, 2.0; 95% CI, 1.4-2.9).
  • The overall associations with cardia cancer were heterogeneous, although stratification by study location provided homogeneous results for populations from the United States or Europe.
  • A high BMI was weakly associated with the risk of cardia adenocarcinoma (OR, 1.5; 95% CI, 1.3-1.8; P(heterogeneity) = 0.38).
  • CONCLUSIONS: Pooled results from observational studies support a positive association between high BMI and the risk for esophageal and possibly for cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Body Mass Index. Esophageal Neoplasms / epidemiology. Obesity / complications. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Cardia. Female. Humans. Male. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702363.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08DK002697; United States / NIDDK NIH HHS / DK / R01 DK63616
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


10. Hanyu T, Kanda T, Matsuki A, Hasegawa G, Yajima K, Tsuchida M, Kosugi S, Naito M, Hatakeyama K: Endobronchial metastasis from adenocarcinoma of gastric cardia 7 years after potentially curable resection. World J Gastrointest Surg; 2010 Aug 27;2(8):270-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial metastasis from adenocarcinoma of gastric cardia 7 years after potentially curable resection.
  • Endobronchial metastasis (EBM) is a rare form of metastasis from extrapulmonary malignant tumors, although there are few reports of EBM from gastric cancer specifically.
  • We report the case of a 51-year-old woman who had undergone gastrectomy for advanced gastric cancer seven years previously but was diagnosed with a solitary lung tumor by follow-up computed tomography.
  • On diagnosis of primary lung cancer, she underwent pulmonary lobectomy, but immunohistochemical examination confirmed the resected tumor to be an EBM from the gastric cancer.
  • Six months later, she was diagnosed with peritoneal metastases and underwent chemotherapy with gastric cancer regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160887.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999249
  • [Keywords] NOTNLM ; Endobronchial metastasis / Gastric cancer / Immunohistochemistry
  •  go-up   go-down


11. Miao X, Zhang X, Zhang L, Guo Y, Hao B, Tan W, He F, Lin D: Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Gastroenterology; 2006 Aug;131(2):420-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer.
  • This study examined the effects of ADPRT Val762Ala and XRCC1 Arg399Gln polymorphisms on ADPRT-XRCC1 interaction in vitro in cells and their contributions to gastric cardia adenocarcinoma (GCA) risk.
  • [MeSH-major] ADP Ribose Transferases / genetics. Cardia / pathology. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890595.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 2.4.2.- / ADP Ribose Transferases
  •  go-up   go-down


12. Créhange G, Bonnetain F, Chauffert B, Rat P, Bedenne L, Maingon P: [Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?]. Cancer Radiother; 2008 Sep;12(5):365-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?].
  • Adenocarcinoma of the oesophagogastric junction has an ominous prognosis.
  • Until now, oesophageal adenocarcima care was close to the squamous cell cancer one whereas adenocarcinoma of the cardia was mixed with gastric cancers.
  • Results from several phase-III studies or meta-analysis allowed to define three therapeutic strategies applicable to adenocarcinoma of the oesophagus and the oesophagogastric junction.
  • We have performed a review of the literature with a methodological analysis of data with a high level of evidence in order to advise perioperative treatment guidelines for patients with a resectable adenocarcinoma of the lower oesophagus or gastro-oesophageal junction.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Postoperative Care. Preoperative Care. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18420440.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 59
  •  go-up   go-down


13. Cervantes DT, Fischbach LA: Gastric cardia adenocarcinoma in Taiwanese men: positive associations due to selection bias. World J Gastroenterol; 2010 Mar 28;16(12):1553-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cardia adenocarcinoma in Taiwanese men: positive associations due to selection bias.
  • The factors associated with an increase in gastric cardia adenocarcinoma are poorly understood.
  • In conducting studies to establish the relationship between potential risk factors and gastric cardia adenocarcinoma, it is necessary to carefully consider the role of bias.
  • In a recently published study, the reported associations between H. pylori as well as post-meal physical exertion and gastric cardia adenocarcinoma may have been greatly influenced by selection bias.
  • [MeSH-major] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori / pathogenicity. Stomach Neoplasms / etiology
  • [MeSH-minor] Asian Continental Ancestry Group. Cardia. Case-Control Studies. Humans. Male. Reproducibility of Results. Risk Assessment. Risk Factors. Selection Bias. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):687-96 [16997153.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Oct;15(4):697-714 [17030268.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(2):205-14 [17382273.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):351-65 [18318820.001]
  • [Cites] World J Gastroenterol. 2009 Nov 21;15(43):5472-80 [19916179.001]
  • [CommentOn] World J Gastroenterol. 2009 Nov 21;15(43):5472-80 [19916179.001]
  • (PMID = 20333802.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846267
  •  go-up   go-down


14. Wu X, Chen VW, Ruiz B, Andrews P, Su LJ, Correa P: Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences. Cancer; 2006 Feb 1;106(3):683-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences.
  • BACKGROUND: The authors examined subsite-specific and histology-specific esophageal and gastric carcinoma incidence patterns among the Asians/Pacific Islander (API) population in the United States and compared them with those among whites and blacks.
  • METHODS: Data on newly diagnosed esophageal and gastric carcinomas during 1996-2000 were obtained from 24 population-based central cancer registries, representing approximately 80% of the API population in the United States.
  • Adenocarcinoma accounted for <20% of all esophageal carcinomas.
  • The rates of esophageal adenocarcinoma were significantly lower among APIs than among both whites and blacks both males and females.
  • The majority of gastric carcinomas among APIs were noncardia adenocarcinoma, whereas cardia adenocarcinoma accounted for only 11% of gastric carcinomas among API males and 6% of gastric carcinomas among API females.
  • The age-adjusted incidence rate of cardia adenocarcinoma was 23% lower among API males compared with white males, but it was 26% higher compared with black males.
  • In contrast, the rates of noncardia adenocarcinoma among APIs were approximately 3.7 times the rate among whites for both males and females and 33% higher than the rate among blacks.
  • The reasons for significantly higher rates of noncardia adenocarcinoma among APIs compared with whites and blacks need further investigation.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / ethnology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / ethnology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / ethnology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 16388522.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N02-PC-44401
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Jansson C, Johansson AL, Nyrén O, Lagergren J: Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1754-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study.
  • BACKGROUND: The increase in esophageal adenocarcinoma incidence in developed countries remains unexplained.
  • Although low socioeconomic status (SES) is linked to an increased risk of esophageal squamous cell carcinoma (SCC), the relation with adenocarcinoma is uncertain.
  • METHODS: We addressed the importance of various socioeconomic factors in a Swedish population-based case-control study, where 189 and 262 cases of esophageal adenocarcinoma and the gastric cardia, respectively, 167 cases of esophageal SCC, and 820 control participants underwent personal interviews.
  • RESULTS: The risk of both esophageal adenocarcinoma and SCC increased with decreasing SES; unskilled workers had 3.7-fold (95% CI, 1.7-7.7) and 2.1-fold (95% CI, 1.0-4.7) increased risks, respectively, compared with age- and sex-comparable professionals.
  • Adjustment for reflux symptoms, body mass, and tobacco smoking attenuated the excess risk for esophageal adenocarcinoma, whereas adjustment for Helicobacter pylori infection in a subset of the interviewed participants did not influence the results.
  • CONCLUSIONS: Esophageal adenocarcinoma and SCC are both linked to low SES and a life without a partner.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Population Surveillance / methods. Socioeconomic Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030113.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Capellá G, Pera G, Sala N, Agudo A, Rico F, Del Giudicce G, Plebani M, Palli D, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Berrino F, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key T, Bingham S, Caldas C, Linseisen J, Nagel G, Overvad K, Tjonneland A, Boshuizen HC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Kaaks R, Riboli E, González CA: DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol; 2008 Dec;37(6):1316-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study.
  • BACKGROUND: The contribution of genetic variation in DNA repair genes to gastric cancer (GC) risk remains essentially unknown.
  • Method A nested case control study within the EPIC cohort was performed including 246 gastric adenocarcinomas and 1175 matched controls.
  • RESULTS: No association was observed for any of these polymorphisms with stomach cancer risk.
  • This is the first prospective study suggesting that individual variation in DNA repair may be relevant for gastric carcinogenesis, a finding that will require further confirmation validation in larger independent studies.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Repair / genetics. Gastritis, Atrophic / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Antibodies, Bacterial / blood. Biomarkers / blood. Cardia / pathology. Case-Control Studies. Chronic Disease. Europe. Female. Follow-Up Studies. Gene Frequency. Genes, p53. Genetic Predisposition to Disease. Helicobacter Infections / complications. Helicobacter Infections / immunology. Helicobacter pylori / immunology. Humans. Male. Middle Aged. Odds Ratio. Pepsinogen A / blood. Prospective Studies. Risk. Xeroderma Pigmentosum Group D Protein / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641418.001).
  • [ISSN] 1464-3685
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Biomarkers; 9001-10-9 / Pepsinogen A; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


17. Buchs NC, Bucher P, Pugin F, Hagen ME, Morel P: Robot-assisted oncologic resection for large gastric gastrointestinal stromal tumor: a preliminary case series. J Laparoendosc Adv Surg Tech A; 2010 Jun;20(5):411-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted oncologic resection for large gastric gastrointestinal stromal tumor: a preliminary case series.
  • BACKGROUND: Laparoscopic resection of gastric gastrointestinal stromal tumor (GIST) has been shown as feasible and safe in terms of oncologic results.
  • The robotic approach may, by its characteristics, enable the surgeon to perform atypical gastrectomies in an unfavorable location (i.e., close to pylorus or cardia).
  • Its use in oncologic gastric surgery has been poorly defined and has never been reported for GIST.
  • MATERIALS AND METHODS: All patients who underwent robotic-assisted gastric resection for GIST at a single institution from 2006 to 2009 were prospectively followed-up.
  • One patient had a conversion to open surgery because of a suspicion of diffuse adenocarcinoma on fresh frozen section and necessitated a total gastrectomy with a radical lymph node dissection.
  • CONCLUSIONS: The da Vinci robot (Intuitive Surgical, Inc., Sunnyvale, CA) is a valuable instrument for oncologically safe resection with esogastric or duodenogastric junction preservation for an unfavorably located gastric GIST.
  • Moreover, the three-dimensional, high-definition vision, instrument mobility, and ease of performing a difficult suturing enable a safe, large atypical gastrectomy, close to the pylorus or cardia.
  • [MeSH-major] Gastrectomy / instrumentation. Gastrointestinal Stromal Tumors / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459328.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E: Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol; 2009 Feb;16(2):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection.
  • The surgical strategy for adenocarcinoma of the esophagogastric junction is still controversial.
  • The aim of this study was to evaluate surgical results of the abdominal-transhiatal approach for 100 consecutively operated type II and III cardia adenocarcinoma, to clarify clinicopathological differences between these tumors, and to define prognostic factors.
  • A prospectively maintained database identified 100 consecutively operated patients with Siewert type II and III cardia adenocarcinoma.
  • True carcinoma of the cardia may be a distinct clinical entity with a more aggressive natural history than subcardial gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia / pathology. Cardia / surgery. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Jul;16(7):2074-5; author reply 2076 [19365623.001]
  • (PMID = 19050964.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J: Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer; 2006 Jul 3;95(1):118-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
  • Standardised incidence ratios (SIRs) of oesophageal and gastric cancer represented relative risks.
  • Among 138 885 cohort members contributing with 1 075 724 person-years of follow-up, we found a nonsignificantly increased risk of oesophageal adenocarcinoma during the potential tamoxifen exposure period (SIR 1.60, 95% confidence interval (CI) 0.83-3.08), but the risk estimates decreased with increasing latency interval.
  • No increased risk of cardia adenocarcinoma was identified in either period.
  • The risk of non-cardia gastric adenocarcinoma was increased in the potential tamoxifen period (SIR 1.27, 1.03-1.57), and almost doubled (SIR 1.86, 95% CI 1.10-3.14) in the period of longest latency (10-14 years).
  • We concluded that there might be a link between tamoxifen and risk of non-cardia gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Breast Neoplasms / drug therapy. Carcinoma, Squamous Cell / chemically induced. Esophageal Neoplasms / chemically induced. Lung Neoplasms / chemically induced. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Ann Oncol. 2000 Dec;11(12):1537-43 [11205460.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15 [12160084.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):529-33 [4055127.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):117-20 [2563046.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1007-10 [2667745.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1013-7 [2072407.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 19;88(12):832-4 [8637050.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):859-61 [16189516.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • (PMID = 16755290.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ PMC2360495
  •  go-up   go-down


20. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J, Asia-Pacific Gastric Cancer Consensus Conference: Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol; 2008 Mar;23(3):351-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asia-Pacific consensus guidelines on gastric cancer prevention.
  • BACKGROUND AND AIM: Gastric cancer is a major health burden in the Asia-Pacific region but consensus on prevention strategies has been lacking.
  • We aimed to critically evaluate strategies for preventing gastric cancer.
  • RESULTS: Helicobacter pylori infection is a necessary but not sufficient causal factor for non-cardia gastric adenocarcinoma.
  • A high intake of salt is strongly associated with gastric cancer.
  • Fresh fruits and vegetables are protective but the use of vitamins and other dietary supplements does not prevent gastric cancer.
  • Host-bacterial interaction in H. pylori infection results in different patterns of gastritis and differences in gastric acid secretion which determine disease outcome.
  • A positive family history of gastric cancer is an important risk factor.
  • Low serum pepsinogens reflect gastric atrophy and may be useful as a marker to identify populations at high risk for gastric cancer. H. pylori screening and treatment is a recommended gastric cancer risk reduction strategy in high-risk populations. H. pylori screening and treatment is most effective before atrophic gastritis has developed.
  • It does not exclude the existing practice of gastric cancer surveillance in high-risk populations.
  • In populations at low risk for gastric cancer, H. pylori screening is not recommended.
  • CONCLUSION: A strategy of H. pylori screening and eradication in high-risk populations will probably reduce gastric cancer incidence, and based on current evidence is recommended by consensus.
  • [MeSH-major] Adenocarcinoma / prevention & control. Anticarcinogenic Agents / therapeutic use. Biomarkers, Tumor / analysis. Helicobacter Infections / drug therapy. Helicobacter pylori. Mass Screening. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318820.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; 0 / Pepsinogens; 0 / Sodium Chloride, Dietary; 0 / Vitamins; PQ6CK8PD0R / Ascorbic Acid
  • [Number-of-references] 140
  •  go-up   go-down


21. Jovanović I, Alempijević T, Milosavljević T, Popović D, Bjelović M, Micev M, Pesko P: [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients]. Srp Arh Celok Lek; 2009 May-Jun;137(5-6):249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients].
  • INTRODUCTION In the past two decades, the increased frequency of distal esophageal adenocarcinoma, esophagogastric junction and proximal gastric adenocarcinoma has been observed.
  • The vast majority of these tumours are diagnosed in advanced stages, when the prognosis is poorer than in other gastric cancers.
  • OBJECTIVE: The aim of our study was to analyze the demographic and clinicopathological characteristics of patients operated on for Barrett's, cardia and distal gastric adenocarcinomas, as well as to study the influence of manifestations of each cancerogenetic indication on the studied clinicopathological parameters and to analyze the 5-year survival rate of patients surgically treated for cardia adenocarcinoma in relation to the patients operated on for distal gastric adenocarcinoma.
  • In the patients operated on for Barrett's and cardia cancers, the tumours invaded more deeply the wall layers, i.e. they were significantly more invasive than the distal gastric tumour.
  • The lymph node involvement was present in 87.5% of patients with Barrett's cancer, in 80% with cardia cancer and in 87% with distal gastric cancer.
  • The 3-year survival rate of patients operated on for cardia cancer was 47.4% and the 5-year survival rate was 31.6%, while the 3-year survival rate of patients operated on for distal gastric cancer was 46.2% and the 5-year survival rate was 34.6%.
  • CONCLUSION: At the time of diagnosis cardia cancer and cancers developed at the location of the Barrett's oesophagus, developed significant deeper per continuitatem than gastric cancer.
  • There were no other differences in regard to the analyzed clinicopathological parameters among the tumours of these three locations, and there was no difference between the 3-year and 5-year survival rate between the patients operated on for gastric cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / complications. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594065.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


22. Yamamoto J, Ohshima K, Kohno S, Ichimiya H, Nakagaki M, Yao T, Iwasaki H, Ikeda S: Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case. Surg Today; 2005;35(6):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case.
  • Extremely well differentiated primary gastric adenocarcinoma, which accounts for less than 0.2% of all gastric cancers, is associated with a better prognosis than other types of differentiated adenocarcinoma.
  • Among 2070 gastric carcinomas, diagnosed between 1983 and 2002 at Fukuoka University Hospital and Hamanomachi Hospital, there were three cases of primary extremely well differentiated adenocarcinoma.
  • We report the clinicopathological details of one case of primary gastric extremely well differentiated adenocarcinoma.
  • A 57-year-old man was reffered to our hospital for investigation and treatment of a gastric tumor.
  • Macroscopically, the surgical specimen contained a submucosal tumor, and histological examination revealed extremely well differentiated adenocarcinoma.
  • Although this type of carcinoma is very rare, it should be considered in the differential diagnosis of esophageal and gastric mucosal lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Achalasia / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Cardia / pathology. Cell Differentiation. Cholecystectomy. Endoscopy, Digestive System. Esophagus / radiography. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • Genetic Alliance. consumer health - Achalasia.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912298.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Wang GQ, Wei WQ, Zhang JH: [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases]. Ai Zheng; 2007 Nov;26(11):1153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases].
  • BACKGROUND & OBJECTIVE: The survival time of untreated advanced gastric cardiac adenocarcinoma patients is about 8-9 months.
  • This study was to observe the natural progression of untreated early stage gastric cardiac adenocarcinoma.
  • METHODS: In 1987, at a high risk area of esophageal cancer, 851 patients with a previous cytologic diagnosis of esophageal dysplasia were re-examined by endoscopy, and 43 of them were diagnosed histologically as gastric cardiac adenocarcinoma.
  • RESULTS: Of the 17 untreated patients, 12 were died of gastric cardiac adenocarcinoma, 5 were died of non-cancer diseases; 13 had survived for over 5 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Disease Progression. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991310.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


24. Lazăr D, Tăban S, Sporea I, Dema A, Cornianu M, Lazăr E, Goldiş A, Vernic C: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol; 2010;51(4):655-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up.
  • AIM: The analysis of immunohistochemical expression of the Ki-67 antigen using the monoclonal antibody MIB1 in 61 patients with gastric cancer, the correlation with clinicopathological factors and the prognosis of the patients.
  • RESULTS: In the gastric carcinomas, we remarked various Ki-67 scores.
  • For a proper grouping of the results, we classified gastric carcinomas into two categories: carcinomas with high MI Ki-67 (≥45%) and carcinomas with low MI Ki-67 (≤45%).
  • We noticed an increased frequency of high MI Ki-67 carcinomas in elderly patients (p=0.03) and also in the tumors developed at cardia level and those extended in the entire stomach in the moment of diagnosis (p<0.001).
  • The histological forms associated to high Ki-67 values are represented by the anaplastic carcinoma (100% of cases) and papillary adenocarcinoma (60% of cases).We observed a close correlation between the degree of tumor differentiation and the Ki-67 score (p<0.001).
  • The results of our study do not reveal any correlation between the Lauren's Classification of gastric carcinomas, the lymphovascular invasion, the depth of tumor invasion, the TNM stage and the Ki-67 score (p>0.05).
  • [MeSH-major] Ki-67 Antigen / metabolism. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103622.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


25. Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B, Mayne S, Fraumeni J Jr, Gammon MD: IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer; 2009 Dec 1;125(11):2673-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas.
  • We tested the hypothesis that the common nonsynonymous genetic variants in M6P/IGF2R c.901C > G (Leu > Val) in exon 6 and c.5002G > A (Gly > Arg) in exon 34 are associated with risk of esophageal and gastric cancers.
  • Study participants in this population-based study comprise 197 controls and 182 cases, including 105 with esophageal-gastric cardia adenocarcinoma (EGA), 57 with noncardia gastric adenocarcinoma and 20 with esophageal squamous (ES) cell carcinoma.
  • Among white males, odds ratios (ORs) were elevated in relation to carrying at least 1 c.901C > G allele for EGA [OR = 1.9; 95% confidence intervals (CIs) = 1.0-3.6] and noncardia gastric cancer (OR = 2.5; 95% CI = 1.2-5.5), but not ES.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857229 for PMID:19626700 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Mar 16;19(12):1572-8 [10734317.001]
  • [Cites] J Mol Endocrinol. 2009 Apr;42(4):341-56 [19208780.001]
  • [Cites] Mol Cell. 2000 Apr;5(4):707-16 [10882106.001]
  • [Cites] Hum Mutat. 2001;18(1):25-31 [11438990.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]
  • [Cites] Endocrinology. 2003 Mar;144(3):955-66 [12586773.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):580-4 [1846448.001]
  • [Cites] Stem Cells. 1997;15(3):190-7 [9170210.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):269-81 [9516081.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):607-9 [15765396.001]
  • [Cites] BMC Genet. 2005;6:22 [15885138.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):971-81 [16841264.001]
  • [Cites] Acta Paediatr. 2007 Mar;96(3):363-7 [17407457.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1667-74 [17684144.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1039-46 [17665311.001]
  • [Cites] Structure. 2007 Sep;15(9):1065-78 [17850746.001]
  • [ErratumIn] Int J Cancer. 2010 Feb 1;126(3):799. Calingeart, Brian [corrected to Calingaert, Brian]
  • (PMID = 19626700.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K05 CA124911; United States / NCI NIH HHS / CA / CA104517-02; United States / NCI NIH HHS / CA / CA104517-03; United States / NCI NIH HHS / CA / K01 CA104517-02; United States / NCI NIH HHS / CA / K01 CA104517; United States / NCI NIH HHS / CA / K01 CA104517-05; United States / NCI NIH HHS / CA / K01 CA104517-03
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, IGF Type 2
  • [Other-IDs] NLM/ NIHMS137939; NLM/ PMC3008656
  •  go-up   go-down


26. Ang TL, Ng TM, Fock KM, Teo EK: Accuracy of endoscopic ultrasound staging of gastric cancer in routine clinical practice in Singapore. Chin J Dig Dis; 2006;7(4):191-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoscopic ultrasound staging of gastric cancer in routine clinical practice in Singapore.
  • OBJECTIVE: Endoscopic ultrasound has emerged as the leading modality to assess the T and N stage in gastric cancer.
  • METHODS: Over a period of 7 years, 77 patients (male: 70%; median age 62.8 years) with gastric cancer underwent preoperative staging with endoscopic ultrasound.
  • RESULTS: The tumor locations were: cardia: 13; corpus: 20; incisura: 19; antrum: 25.
  • The majority was poorly differentiated (57.1%); 26% were moderately differentiated and 16.9% were well differentiated adenocarcinoma.
  • CONCLUSION: Endoscopic ultrasound is useful for the T staging of gastric cancer, with an overall accuracy rate of 77%, and up to 93% for T1 lesions.
  • [MeSH-major] Endosonography. Neoplasm Staging / methods. Stomach Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054580.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


27. Vissers KJ, Dinjens WN, Riegman PH, Tilanus HW, van Dekken H: Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma. Anticancer Res; 2005 Mar-Apr;25(2A):913-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma.
  • BACKGROUND: Oesophageal (Barrett's) and gastric cardia adenocarcinomas are cancers arising at and around the gastro-oesophageal junction.
  • In addition, 40 gastric cardia cancers were investigated to compare the pattern of imbalance at these loci.
  • RESULTS: Overall, the number of allelic loss was higher in Barrett's cancers than in gastric cardia carcinomas (p=0.04).
  • In gastric cardia cancers, loss ranged from 12% to 27% (of informative cases), being most frequent at marker D7S3037.
  • The difference between oesophageal and gastric adenocarcinomas was highest for polymorphic marker D7S483 (p=0.05).
  • CONCLUSION: Marker D7S483 can aid in discriminating oesophageal (Barrett's) and gastric cardia carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance. Barrett Esophagus / genetics. Cardia / pathology. Chromosomes, Human, Pair 7 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868927.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


28. Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, Liu B, Fan JH, Abnet CC: Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut; 2009 May;58(5):636-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.
  • OBJECTIVE: Low serum pepsinogen I (PGI) and low pepsinogen I/pepsinogen II ratio (PGI/II ratio) are markers of gastric fundic atrophy.
  • We aimed to prospectively test the association between serum PGI/II ratio and risks of gastric non-cardia adenocarcinoma, gastric cardia adenocarcinoma, and oesophageal squamous cell carcinoma (OSCC).
  • RESULTS: Compared to subjects with PGI/II ratio of >4, those with <or=4 had hazard ratios (HRs) (95% CIs) of 2.72 (1.77 to 4.20) and 2.12 (1.42 to 3.16) for non-cardia and cardia gastric adenocarcinomas, respectively.
  • The nonlinear continuous models suggested that any single cut point collapsed subjects with dissimilar gastric adenocarcinoma risks, and that using cut points was not an efficient use of data in evaluating these associations.
  • CONCLUSION: In this prospective study, we found similar and significantly increased risks of non-cardia and cardia gastric adenocarcinomas in subjects with low PGI/II ratio but little evidence for an association with the risk of OSCC.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Mar10;109(1):138-43 [14735480.001]
  • [Cites] Jpn J Cancer Res. 1995 Jan;86(1):64-71 [7737912.001]
  • [Cites] J Med Screen. 2004;11(3):141-7 [15333273.001]
  • [Cites] Gastroenterology. 1972 Oct;63(4):584-92 [5077145.001]
  • [Cites] Gastroenterology. 1982 Jul;83(1 Pt 2):204-9 [7084603.001]
  • [Cites] Clin Chim Acta. 1987 Mar 16;163(2):191-8 [3568423.001]
  • [Cites] Clin Invest Med. 1987 May;10(3):215-21 [3113799.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):113-7 [8467245.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] J Clin Gastroenterol. 1993 Jul;17(1):84 [8409305.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):461-6 [8220091.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] Int J Cancer. 2009 May 1;124(9):2135-8 [19107937.001]
  • [Cites] Dig Dis Sci. 1997 Jul;42(7):1383-7 [9246033.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):1032-6 [15742409.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):463-9 [15688378.001]
  • [Cites] Gut. 2005 Jun;54(6):764-8 [15888780.001]
  • [Cites] J Infect Dis. 2005 Jun 15;191(12):2075-81 [15897993.001]
  • [Cites] Am J Epidemiol. 2006 Apr 1;163(7):629-37 [16443800.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1083-94 [16775164.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] Gut. 2007 Apr;56(4):457-9 [17369378.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1603-9 [17488251.001]
  • [Cites] Gut. 2008 Mar;57(3):298-305 [17965056.001]
  • [Cites] Jpn J Clin Oncol. 2008 Apr;38(4):259-67 [18344316.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):874-81 [18484586.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):456-60 [18844222.001]
  • [Cites] BMC Med Res Methodol. 2002;2:4 [11914137.001]
  • [Cites] Gut. 2002 Sep;51(3):457-8 [12171977.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):107-12 [11219766.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • (PMID = 19136509.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / N01-RC-47702; United States / NCI NIH HHS / SC / N01-SC-91030; United States / CCR NIH HHS / RC / N01RC47701; United States / CCR NIH HHS / RC / N01RC47702; United States / Intramural NIH HHS / / ZIA CP000112-05; United States / CCR NIH HHS / RC / N01-RC-47701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 61536-72-9 / Pepsinogen C; 9001-10-9 / Pepsinogen A
  • [Other-IDs] NLM/ NIHMS159682; NLM/ PMC2792746
  •  go-up   go-down


29. Godiris-Petit G, Munoz-Bongrand N, Honigman I, Cattan P, Sarfati E: [Minimally invasive esophagectomy: prospective evaluation of laparoscopic gastric mobilization]. Ann Chir; 2006 Mar;131(3):189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimally invasive esophagectomy: prospective evaluation of laparoscopic gastric mobilization].
  • METHODS: From July 2001 to June 2004, 20 patients underwent esophagectomy with laparoscopic gastric mobilization (LGM) for squamous cell carcinoma (N=11), adenocarcinoma (N=7), Barrett's esophagus with high-grade dysplasia (N=1), and long peptic stricture (N=1).
  • Tumours (N=19) were located on the cardia (N=5), on the lower third of the oesophagus (N=10), on the median third (N=3), and on the upper third (N=1).
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466684.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


30. Okabayashi T, Kobayashi M, Sugimoto T, Akimori T, Namikawa T, Okamoto K, Maeda H, Araki K: Clinicopathological features of type 1 gastric carcinoma: the need to be cautious of superficial lesion surrounding type 1 gastric carcinoma. Hepatogastroenterology; 2006 Mar-Apr;53(68):313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of type 1 gastric carcinoma: the need to be cautious of superficial lesion surrounding type 1 gastric carcinoma.
  • BACKGROUND/AIMS: Gastric carcinoma (GC) is one of the most common malignant tumors of the digestive tract and the incidence of adenocarcinoma of the upper one-third of the stomach has increased recently worldwide.
  • RESULTS: The characteristics of patients with Type 1 GC were different from those of patients with non-Type 1 GC: Their tumors were more often in the upper one-third of the stomach (37% vs. 15%), lesions were histologically differentiated in 80% (vs. 56%), and there were more superficial lesions surrounding Type 1 GC (80% vs. 8%).
  • The current series suggested that Type 1 GC are associated frequently with superficial lesions, making local resections more difficult, and that Type 1 GC was similar clinicopathologically to carcinoma of the gastric cardia and had different etiologies contributed to its tumorgenesis, compared with non-Type 1 GC, and Type 1 GC may become the key which solves the problem of carcinoma at the gastric cardia.
  • [MeSH-major] Carcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608047.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


31. Tepes B: Can gastric cancer be prevented? J Physiol Pharmacol; 2009 Dec;60 Suppl 7:71-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can gastric cancer be prevented?
  • Gastric adenocarcinoma is the fourth most common malignancy worldwide and is globally the second leading cause of cancer-related deaths each year.
  • Among the risk factors are genetic factors (genetic diffuse gastric cancer - E-cadherin mutation (CDH1), pro- and anti-inflammatory cytokine genes and innate immune response gene polymorphisms), environmental factors (infection with the bacterium Helicobacter pylori (H. pylori), Epstein-Barr virus, nutrition: nitroso compounds, salt and antioxidants intake) and other factors (pernicious anemia, gastric polyps, gastric surgery, reproductive hormones, smoking).
  • The bacterium H. pylori has been found to be the major carcinogen in gastric cancer development.
  • Approximately 65%-80% of non-cardia gastric adenocarcinoma is attributable to H. pylori infection.
  • One percent of patients infected with H. pylori will develop gastric cancer.
  • American and European guidelines on the management of H. pylori infection recommend H. pylori eradication in all patients with atrophy and/or intestinal metaplasia and in all first-degree relatives of gastric cancer patients.
  • In the Asian Pacific Gastric Cancer Consensus, it was suggested for the first time that it is time for population-based screening and treatment of H. pylori infection in regions with gastric cancer incidence above 20/100000 per year.
  • Population screen and treat of H. pylori infection should be recommended in regions with gastric cancer incidence above 20/100000 per year.
  • This can be a good approach in H. pylori infected patients before they develop premalignant gastric lesions.
  • [MeSH-major] Adenocarcinoma / prevention & control. Stomach Neoplasms / prevention & control
  • [MeSH-minor] Animals. Early Detection of Cancer. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / physiopathology. Helicobacter pylori. Humans. Mass Screening. Patient Education as Topic. Risk Factors. Stomach Diseases / physiopathology. Stomach Diseases / prevention & control. Stomach Diseases / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388948.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 74
  •  go-up   go-down


32. García Rodríguez LA, Lagergren J, Lindblad M: Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut; 2006 Nov;55(11):1538-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
  • BACKGROUND: Gastric acid suppressing drugs (that is, histamine(2) receptor antagonists and proton pump inhibitors) could affect the risk of oesophageal or gastric adenocarcinoma but few studies are available.
  • AIMS: To study the association between long term treatment with acid suppressing drugs and the risk of oesophageal or gastric adenocarcinoma.
  • RESULTS: In 4 340 207 person years of follow up, 287 patients with oesophageal adenocarcinoma, 195 with gastric cardia adenocarcinoma, and 327 with gastric non-cardia adenocarcinoma were identified, and 10 000 control persons were randomly sampled.
  • "Oesophageal" indication for long term acid suppression (that is, reflux symptoms, oesophagitis, Barrett's oesophagus, or hiatal hernia) rendered a fivefold increased risk of oesophageal adenocarcinoma (odds ratio (OR) 5.42 (95% confidence interval (CI) 3.13-9.39)) while no association was observed among users with a group of other indications, including peptic ulcer and "gastroduodenal symptoms" (that is, gastritis, dyspepsia, indigestion, and epigastric pain) (OR 1.74 (95% CI 0.90-3.34)).
  • "Peptic ulcer" indication (that is, gastric ulcer, duodenal ulcer, or unspecified peptic ulcer) was associated with a greater than fourfold increased risk of gastric non-cardia adenocarcinoma among long term users (OR 4.66 (95% CI 2.42-8.97)) but no such association was found in those treated for a group of other indications (that is, "oesophageal" or "gastroduodenal symptoms") (OR 1.18 (95% CI 0.60-2.32)).
  • CONCLUSIONS: Long term pharmacological gastric acid suppression is a marker of increased risk of oesophageal and gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antacids / adverse effects. Esophageal Neoplasms / chemically induced. Stomach Neoplasms / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anti-Ulcer Agents / administration & dosage. Anti-Ulcer Agents / adverse effects. Cardia. Drug Administration Schedule. Epidemiologic Methods. Great Britain / epidemiology. Histamine H2 Antagonists / administration & dosage. Histamine H2 Antagonists / adverse effects. Humans. Middle Aged. Proton Pump Inhibitors


33. Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, Schatzkin A: A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol; 2007 Jun 15;165(12):1424-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes.
  • Rates of esophageal adenocarcinoma and gastric cardia adenocarcinoma have increased, while rates of esophageal squamous cell carcinoma (ESCC) and gastric noncardia adenocarcinoma have decreased, suggesting distinct etiologies.
  • Between 1995/1996 and 2000, 97 incident cases of ESCC, 205 of esophageal adenocarcinoma, 188 of gastric cardia, and 187 of gastric noncardia cancer occurred.
  • Compared with nonsmokers, current smokers were at increased risk for ESCC (hazard ratio (HR) = 9.27, 95% confidence interval (CI): 4.04, 21.29), esophageal adenocarcinoma (HR = 3.70, 95% CI: 2.20, 6.22), gastric cardia (HR = 2.86, 95% CI: 1.73, 4.70), and gastric noncardia (HR = 2.04, 95% CI: 1.32, 3.16).
  • Assuming causality, ever smoking had population attributable risks of 77% (95% CI: 0.55, 0.89) for ESCC, 58% (95% CI: 0.38, 0.72) for esophageal adenocarcinoma, 47% (95% CI: 0.27, 0.63) for gastric cardia, and 19% (95% CI: 0.00, 0.37) for gastric noncardia.
  • For drinkers of more than three alcoholic beverages per day, compared with those whose intake was up to one drink per day, the authors found significant associations between alcohol intake and ESCC risk (HR = 4.93, 95% CI: 2.69, 9.03) but not risk for esophageal, gastric cardia, or gastric noncardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Alcohol Drinking / adverse effects. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Smoking / adverse effects. Stomach Neoplasms / etiology


34. Mehta SP, Bailey D, Davies N: Comparative outcome of oesophagogastric cancer in younger patients. Ann R Coll Surg Engl; 2010 Sep;92(6):515-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The incidence of oesophageal and gastric cardia adenocarcinoma has increased rapidly over the previous two decades.
  • PATIENTS AND METHODS: Every patient diagnosed with oesophageal, junctional or gastric cancer under the age of 55 years and every subsequent patient over the age of 55 years was accepted into this study.
  • Patients under the age of 55 years diagnosed with oesophageal or gastric cancer appear to have a better prognosis than those aged over 55 years.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2005-12 [11467625.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):600-3 [11922553.001]
  • [Cites] Gut. 2002 Aug;51(2):296-7 [12117899.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):417-20 [1558797.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2425-9 [7922995.001]
  • [Cites] Gut. 1997 Oct;41(4):513-7 [9391251.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Am Surg. 2004 Nov;70(11):954-8 [15586504.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):784-91 [15784019.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1725-8 [17024539.001]
  • [Cites] Scand J Gastroenterol. 2007 Jan;42(1):17-22 [17190757.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):957-65 [17313501.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):75-9 [9934734.001]
  • (PMID = 20522292.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3182797
  •  go-up   go-down


35. Sarbia M: The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens. Virchows Arch; 2006 May;448(5):532-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens.
  • The current study was performed to determine whether the histopathological appearance of oesophageal adenocarcinoma (AC) differs significantly from that of cardiac or gastric AC.
  • Therefore, HE-stained slides of 215 primarily resected oesophageal AC, 108 cardiac and 184 gastric AC were classified according to a variety of clinico-pathologic parameters.
  • According to Lauren's classification, oesophageal AC (1.4%) less frequently belonged to the diffuse type than cardiac (2.8%) and gastric AC (23.9%; p<0.0001).
  • Tubular and papillary AC, as defined by the WHO classification, were more frequent among oesophageal (94.4%) than among cardiac (87.0%) and gastric AC (59.2%; p<0.0001).
  • Solid carcinomas, according to Carneiro's classification, were less frequent among oesophageal (2.8%) than among cardiac (10.2%) and gastric AC (9.2%; p<0.0001).
  • Oesophageal AC were graded more frequently G1/G2 (53.9%) than cardiac (30.6%) and gastric AC (27.7%; p<0.0001).
  • In conclusion, oesophageal AC displays the same histological spectrum as cardiac and gastric AC.
  • However, the relative proportion of differentiated, gland-forming carcinomas is significantly more frequent in the oesophagus than in the cardia and in the stomach.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Esophageal Neoplasms / classification. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):703-10 [15557945.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Surgery. 2001 Jan;129(1):103-9 [11150040.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):444-9 [15297937.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):224-8 [15197775.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):333-6 [7729944.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):95-9 [8270616.001]
  • [Cites] Virchows Arch. 2000 Oct;437(4):348-50 [11097357.001]
  • [Cites] Am J Surg. 1985 Sep;150(3):365-9 [4037198.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):183-91 [7832278.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1040-6 [12917759.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):33-40 [11141476.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):505-12 [14629106.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2429-37 [10861416.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • (PMID = 16498532.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


36. Lee HS, Cheung DY, Kim JI, Cho SH, Park SH, Han JY, Kim JK: A case of spontaneous regression of advanced gastric cancer. J Korean Med Sci; 2010 Oct;25(10):1518-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of spontaneous regression of advanced gastric cancer.
  • Esopahgogastroduodenoscopy showed the diffuse infiltrative type of gastric cancer encircling from the cardia to the lower body.
  • On abdominal computerized tomography, the gastric wall was diffusely thickened with overlying mucosal enhancement without lymph node involvement.
  • Histologic examination revealed poorly differentiated adenocarcinoma.
  • On esophagogastroduodenoscopy, the gastric mucosa of the body looked normal without any dysplastic change.
  • Abdominal CT revealed a decreased thickening of the gastric wall of the body.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2007 Jun;156(6):617-21 [17535860.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1296-300 [18951206.001]
  • [Cites] Urol Int. 2001;66(2):119-20 [11223759.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(5):335-6 [11315723.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(5):396-8 [12487751.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Abdom Imaging. 2005 Nov-Dec;30(6):734-7 [16252150.001]
  • [Cites] Med J Aust. 1980 Feb 9;1(3):136-7 [6990211.001]
  • [Cites] J Surg Oncol. 1981;17(3):201-9 [6166811.001]
  • [Cites] Dig Dis Sci. 1981 Nov;26(11):1045-50 [6271517.001]
  • [Cites] Acta Oncol. 1990;29(5):545-50 [2206563.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):621-2 [7819077.001]
  • [Cites] Ann Hematol. 1996 Oct;73(4):189-93 [8890708.001]
  • [Cites] N Engl J Med. 1972 Nov 16;287(20):1013-7 [4650967.001]
  • (PMID = 20890436.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Hypoglycemic Agents
  • [Other-IDs] NLM/ PMC2946665
  • [Keywords] NOTNLM ; Advanced Gastric Cancer / Neoplasm Regression, Spontaneous
  •  go-up   go-down


37. van den Brandt PA, Goldbohm RA: Nutrition in the prevention of gastrointestinal cancer. Best Pract Res Clin Gastroenterol; 2006;20(3):589-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overweight and obesity are important risk factors for adenocarcinoma (but not squamous carcinoma) of the esophagus, gastric cardia carcinoma (but not noncardia carcinoma), and colorectal cancer, the latter in particular among men.
  • Alcohol consumption is a risk factor for squamous carcinoma (but not adenocarcinoma) of the esophagus, gastric cancer and colorectal cancer.
  • Selenium may be inversely related to esophageal and gastric cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782531.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 99
  •  go-up   go-down


38. McColl KE: Cancer of the gastric cardia. Best Pract Res Clin Gastroenterol; 2006;20(4):687-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the gastric cardia.
  • Current evidence indicates that cardia cancers are of at least two distinct and disparate aetiologies.
  • One type resembles cancer of the more distal stomach (Type A), being a consequence of atrophic gastritis due to Helicobacter pylori infection or more rarely autoimmune atrophic gastritis.
  • Another type (Type B) resembles oesophageal adenocarcinoma and is likely to be a consequence of short-segment gastro-oesophageal reflux disease.
  • The two cancers are themselves indistinguishable but examination of the gastric phenotype indicates the aetiology: Type A occurring in patients with evidence of atrophic gastritis whereas Type B occurs in subjects with healthy acid secreting stomachs.
  • In subjects with healthy acid secreting stomachs the cardia has a specific luminal chemistry remaining highly acidic and unbuffered following a meal and having very active nitrosative chemistry due to the acidification of nitrite in saliva.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997153.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


39. Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, Rakhshani N, Didevar R, Sotoudeh M, Zolfeghari AA, McColl KE: Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut; 2008 Mar;57(3):298-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer.
  • INTRODUCTION: Atrophic gastritis is a risk factor for non-cardia gastric cancer, and gastro-oesophageal reflux disease (GORD) for oesophageal adenocarcinoma.
  • The role of atrophic gastritis and GORD in the aetiology of adenocarcinoma of the cardia remains unclear.
  • We have investigated the association between adenocarcinoma of the different regions of the upper gastrointestinal tract and atrophic gastritis and GORD symptoms.
  • METHODS: 138 patients with upper GI adenocarcinoma and age- and sex-matched controls were studied.
  • Lauren classification of gastric cancer was used to subtype gastric and oesophageal adenocarcinoma.
  • RESULTS: Non-cardia cancer was associated with atrophic gastritis but not with GORD symptoms; 55% of these cancers were intestinal subtype.
  • Oesophageal adenocarcinoma was associated with GORD symptoms, but not with atrophic gastritis; 84% were intestinal subtype.
  • Cardia cancer was positively associated with both severe gastric atrophy [OR, 95% CI: 3.92 (1.77 to 8.67)] and with frequent GORD symptoms [OR, 95% CI: 10.08 (2.29 to 44.36)] although the latter was only apparent in the non-atrophic subgroup and in the intestinal subtype.
  • The association of cardia cancer with atrophy was stronger for the diffuse versus intestinal subtype and this was the converse of the association observed with non-cardia cancer.
  • CONCLUSION: These findings indicate two distinct aetiologies of cardia cancer, one arising from severe atrophic gastritis and being of intestinal or diffuse subtype similar to non-cardia cancer, and one related to GORD and intestinal in subtype, similar to oesophageal adenocarcinoma.
  • Gastric atrophy, GORD symptoms and histological subtype may distinguish between gastric versus oesophageal origin of cardia cancer.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Gastritis, Atrophic / complications. Gastroesophageal Reflux / complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965056.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CZB/4/485
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 61536-72-9 / Pepsinogen C; 9001-10-9 / Pepsinogen A
  •  go-up   go-down


40. Hold GL, Rabkin CS, Gammon MD, Berry SH, Smith MG, Lissowska J, Risch HA, Chow WH, Mowat NA, Vaughan TL, El-Omar EM: CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev; 2009 Apr;18(2):117-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations.
  • In this study, we assessed the association of these two functional single nucleotide polymorphisms with gastric cancer in two independent Caucasian population-based case-control studies of upper gastrointestinal tract cancer, initially in 312 noncardia gastric carcinoma cases and 419 controls and then in 184 noncardia gastric carcinomas, 123 cardia carcinomas, 159 esophageal cancers, and 211 frequency-matched controls.
  • No significant association was found between the CD14-159C/T and the TLR9-1237T/C promoter polymorphisms and increased risk of gastric cancer.
  • Neither single nucleotide polymorphism has been assessed in a Caucasian gastric cancer case-control study before; although the CD14-159C/T polymorphism has been reported to show no apparent association with H. pylori-related gastric malignancy in a Taiwanese Chinese population.
  • In conclusion, although our earlier preliminary studies suggested that the CD14-159C/T and the TLR9-1237T/C promoter polymorphisms increase the risk of precancerous outcomes, they do not seem to increase the risk of gastric cancer itself.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, CD14 / genetics. European Continental Ancestry Group / genetics. Stomach Neoplasms / genetics. Toll-Like Receptor 9 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2008 Feb;17(1):28-32 [18090907.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Mar;163(4):965-9 [11282774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42 [11470918.001]
  • [Cites] Immunol Lett. 2002 May 1;81(3):165-9 [11947920.001]
  • [Cites] Clin Exp Immunol. 2004 Jun;136(3):521-6 [15147355.001]
  • [Cites] Clin Immunol. 2004 Jul;112(1):85-91 [15207785.001]
  • [Cites] Genes Immun. 2004 Aug;5(5):417-25 [15190267.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 May;20(5):976-83 [10226067.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):871-6 [10362132.001]
  • [Cites] Circulation. 1999 Jun 29;99(25):3218-20 [10385492.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):589-91 [16537722.001]
  • [Cites] Hepatogastroenterology. 2006 Sep-Oct;53(71):807-10 [17086894.001]
  • [Cites] Dig Dis Sci. 2007 Jan;52(1):254-61 [17171451.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • (PMID = 19337058.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K05 CA124911; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057949-03; United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9
  • [Other-IDs] NLM/ NIHMS89852; NLM/ PMC2679029
  •  go-up   go-down


41. Gretschel S, Schlag PM: Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach. Recent Results Cancer Res; 2010;182:107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach.
  • The resection of the adenocarcinoma of the esophagogastric junction should be considered to the extent of the lymphatic drainage.
  • As an adenocarcinoma of the esophagogastric junction is located along the borderline between two visceral cavities (mediastinal/abdominal), it can, in principle, metastasize in both cavities.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Sentinel Lymph Node Biopsy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676875.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


42. González CA, Jakszyn P, Pera G, Agudo A, Bingham S, Palli D, Ferrari P, Boeing H, del Giudice G, Plebani M, Carneiro F, Nesi G, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Day NE, Linseisen J, Nagel G, Bergmann MM, Overvad K, Jensen MK, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Ocke M, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Psaltopoulou T, Roukos D, Lund E, Hemon B, Kaaks R, Norat T, Riboli E: Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst; 2006 Mar 1;98(5):345-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC).
  • BACKGROUND: Dietary factors are thought to have an important role in gastric and esophageal carcinogenesis, but evidence from cohort studies for such a role is lacking.
  • We examined the risks of gastric cancer and esophageal adenocarcinoma associated with meat consumption within the European Prospective Investigation Into Cancer and Nutrition (EPIC) cohort.
  • Cox proportional hazard models were used to examine associations between meat intake and risks of cardia and gastric non-cardia cancers and esophageal adenocarcinoma.
  • RESULTS: During a mean follow-up of 6.5 years, 330 gastric adenocarcinoma and 65 esophageal adenocarcinomas were diagnosed.
  • Gastric non-cardia cancer risk was statistically significantly associated with intakes of total meat (calibrated HR per 100-g/day increase = 3.52; 95% CI = 1.96 to 6.34), red meat (calibrated HR per 50-g/day increase = 1.73; 95% CI = 1.03 to 2.88), and processed meat (calibrated HR per 50-g/day increase = 2.45; 95% CI = 1.43 to 4.21).
  • The association between the risk of gastric non-cardia cancer and total meat intake was especially large in H. pylori-infected subjects (odds ratio per 100-g/day increase = 5.32; 95% CI = 2.10 to 13.4).
  • Intakes of total, red, or processed meat were not associated with the risk of gastric cardia cancer.
  • A positive but non-statistically significant association was observed between esophageal adenocarcinoma cancer risk and total and processed meat intake in the calibrated model.
  • In this study population, the absolute risk of development of gastric adenocarcinoma within 10 years for a study subject aged 60 years was 0.26% for the lowest quartile of total meat intake and 0.33% for the highest quartile of total meat intake.
  • CONCLUSION: Total, red, and processed meat intakes were associated with an increased risk of gastric non-cardia cancer, especially in H. pylori antibody-positive subjects, but not with cardia gastric cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Food Habits. Helicobacter Infections / complications. Helicobacter pylori. Meat. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Cardia. Case-Control Studies. Confidence Intervals. Europe / epidemiology. Female. Follow-Up Studies. Humans. Incidence. Life Style. Male. Middle Aged. Odds Ratio. Proportional Hazards Models. Prospective Studies. Risk Assessment. Risk Factors. Surveys and Questionnaires


43. Kimura H, Koyama F: [A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL]. Gan To Kagaku Ryoho; 2006 Feb;33(2):251-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL].
  • Upper GI endoscopy revealed type 3 gastric cancer from the anglus to the cardia.
  • We performed systemic chemotherapy of TS-1, CDDP and peritoneal infusion of docetaxel on the nonresected gastric cancer with peritoneal dissemination.
  • The patient clinically achieved good QOL by this method, which was very effective for nonresected gastric cancer with peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cardia. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Quality of Life. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484867.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


44. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer; 2007;10(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
  • BACKGROUND: MK-1, the target molecule of FU-MK-1, is encoded by the GA733-2 gene, which is currently being used as a target in clinical trials for gastric, intestinal and biliary cancer treatment with monoclonal antibodies.
  • METHODS: The expression of p53 protein and MK-1 antigen was investigated in specimens from 42 patients with gastric carcinoma.
  • MK-1 expression was more frequent in cardia tumors (71%), in large (>3 cm) tumors (60%-64%), and in specimens from patients with more than five metastatic lymph nodes (69%).
  • Of these 20 patients, 15 (52%) had tubular adenocarcinoma (TA) and 5 (38%) had signet ring cell carcinoma. p53 expression was more frequent in the tumors of male patients (55% vs 27%); in poorly differentiated TAs (60% vs 47% in well-to-moderately differentiated TAs); in smaller tumors (< or = 3 cm, 72% vs 43%-50% in larger tumors); in patients with a prominent inflammatory response (61% vs 21%; P < 0.02); and in patients with lymphatic vessel invasion (77% vs 34%; P < 0.02).
  • Most patients with p53- and MK-1-positive gastric carcinomas and those more than five metastatic lymph nodes had a poor prognosis.
  • CONCLUSION: The study found that the expression of both p53 and MK-1 was frequent in aggressive gastric carcinomas; however, extensive lymph node involvement (more than five nodes) was the only significant factor related to overall survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(4):343-7 [8205349.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):211-6 [16616808.001]
  • [Cites] Arch Pathol Lab Med. 1977 Nov;101(11):568-71 [334106.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Br J Cancer. 1994 May;69(5):943-6 [8180028.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2649-55 [7538044.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):653-61 [8398688.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):584-9 [8099338.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):177-80 [8116572.001]
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):231-8 [10761711.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Virchows Arch. 1994;424(2):187-93 [8180781.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):769-76 [12014649.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4866-72 [3015400.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1247-53 [7977948.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2001-7 [12174877.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3952-6 [6744310.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):174-86 [8424417.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2439-47 [7680948.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2443-50 [1933781.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Histopathology. 2004 Apr;44(4):323-31 [15049897.001]
  • (PMID = 17577621.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


45. Ftériche F, Bouzid T, Makni A, Ksantini R, Bdioui H, Chebbi F, Jouini M, Ammous A, Kacem M, Ben Safta Z: [Gastric adenocarcinoma with lymphoid stroma. About nine cases]. Tunis Med; 2007 Aug;85(8):688-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma with lymphoid stroma. About nine cases].
  • AIM: the purpose of this work is to study the pathological features and the outcome of lymphoid stroma gastric carcinoma and its relation with Epstein-Bar Virus (EBV) and the imortance of the EBV serology in detection of early reccurence.
  • METHODS: between january 1990 and december 2004, 155 patients underwent gastric resection for gastric carcinoma.
  • Nine of them had lymphoid stroma gastric carcinoma.
  • A comprison of survival rate of patients beteween current gastric carcinoma and those with lymphoid stroma gatsric carcinoma was done using the Log Rank test.
  • The tumor was in the antrum in 4 cases, in the body of the stomach in 3 cases and in the cardia in 2 cases.
  • The mean tumor size was 8 cm with deep invasion of the stomach wall in 5 cases and ganglionnary invasion in 6 cases out of 9.
  • CONCLUSION: lymphoid stroma gastric carcinoma is a bulky, local disease.
  • Over all survival was better than survival of current gastric carcinoma, although there was no significance.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254293.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


46. Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y: Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol; 2010 Mar;25(3):555-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
  • This study was designed to investigate the correlation of FAS-1377 G/A, -670 A/G and FASL-844 T/C polymorphisms with susceptibility to gastric cardiac adenocarcinoma in a population of a high-incidence region of Hebei Province.
  • METHODS: FAS-1377 G/A, -670 A/G and FASL-844 T/C polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism analysis in 262 gastric cardiac carcinoma (GCA) patients and 524 healthy controls.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, CD95 / genetics. Biomarkers, Tumor / genetics. Cardia. Fas Ligand Protein / genetics. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074157.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / Fas Ligand Protein
  •  go-up   go-down


47. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH: Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control; 2009 Apr;20(3):361-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.
  • A number of risk factors for esophageal and gastric cancers have emerged, yet little is known whether risk factors map to molecular tumor markers such as overexpression of the tumor suppressor TP53.
  • Using a US multicenter, population-based case-control study (170 cases of esophageal adenocarcinomas, 147 gastric cardia adenocarcinomas, 220 non-cardia gastric adenocarcinomas, and 112 esophageal squamous cell carcinomas), we examined whether the risk associated with cigarette smoking, body mass index (BMI), gastroesophageal reflux disease (GERD), and non-steroidal anti-inflammatory drug (NSAID) use varied by P53 overexpression.
  • The proportion of cases overexpressing P53 by tumor subtype was 72% for esophageal adenocarcinoma, 69% for gastric cardia adenocarcinoma, 52% for non-cardia gastric adenocarcinoma, and 67% for esophageal squamous cell carcinoma.
  • For non-cardia gastric cancer however, an association with cigarette smoking was suggested for tumors that do not overexpress P53, whereas larger BMI was related to adenocarcinomas that overexpress P53 versus no overexpression.
  • Overall, this study did not find a clear relationship between P53 protein overexpression and the known risk factors for subtypes of esophageal and gastric cancers.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Vojnosanit Pregl. 2005 Dec;62(12):879-85 [16375215.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2914-8 [8187077.001]
  • [Cites] Carcinogenesis. 1995 May;16(5):993-1002 [7767998.001]
  • [Cites] Pathol Res Pract. 1994 Dec;190(12):1141-8 [7540752.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):425-32 [9028350.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Mod Pathol. 2001 May;14(5):397-403 [11353048.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):233-40 [11902578.001]
  • [Cites] Oncology. 2002;62(2):175-9 [11914604.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1729-35 [14583777.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):779-82 [9332759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):1065-9 [9419404.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Cancer. 1998;77(2):277-86 [9460999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):591-7 [10223186.001]
  • [Cites] J Pathol. 1999 Jan;187(1):8-18 [10341702.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):63-8 [15621992.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):225-30 [15765441.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • (PMID = 18989634.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] None / None / / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057983; None / None / / U01 CA057983-03; United States / Intramural NIH HHS / / Z01 CP010136-12; United States / NCI NIH HHS / CA / U01 CA057923; United States / NCI NIH HHS / CA / U01 CA 57923; United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057983-03; United States / NCI NIH HHS / CA / U01 CA 57983; United States / NCI NIH HHS / CA / U01 CA 57049; None / None / / U01 CA057949-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS100106; NLM/ PMC2726999
  •  go-up   go-down


48. Fujita M, Fujimori T, Chiba T: [The definition of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They proposed that BE was a chance in the esophageal epithelium of any length that can be recognized at endoscopy, and confirmed to have intestinal metaplasia by biopsy of the tubular esophagus and excludes intestinal metaplasia of the cardia.
  • Endoscopically, BE is determined, when 'gastric-appearing mucosa' or apparent 'columnar lined esophagus' is evident proximal to the esophagogastric junction.
  • Histologically, BE has double muscularis mucosae, and contains a mixture cell types; gastric-fundic type epithelium, junctional type epithelium, and specialized columnar epithelium (SCE).
  • On the other hand, BE is premalignant condition for the adenocarcinoma of the esophagus, therefore the features of the BE are researched to prevent and find out earlier development of adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Esophagoscopy. Gastroesophageal Reflux / complications. Humans

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101217.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


49. Bashash M, Shah A, Hislop G, Brooks-Wilson A, Le N, Bajdik C: Incidence and survival for gastric and esophageal cancer diagnosed in British Columbia, 1990 to 1999. Can J Gastroenterol; 2008 Feb;22(2):143-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and survival for gastric and esophageal cancer diagnosed in British Columbia, 1990 to 1999.
  • BACKGROUND: Geographical variation and temporal trends in the incidence of esophageal and gastric cancers vary according to both tumour morphology and organ subsite.
  • The incidence and survival rates for gastric and esophageal carcinoma in British Columbia (BC) between 1990 and 1999 are described.
  • RESULTS: Between 1990 and 1999, 1741 esophageal cancer cases and 3431 gastric cancer cases were registered in BC.
  • There was an increase in the incidence of adenocarcinoma of the esophagus over time (EAPC=9.6%) among men, and of gastric cardia cancer among both women (EAPC=9.2%) and men (EAPC=3.8%).
  • Patients with proximal gastric (cardia) cancer had significantly better survival rates than patients with cancer in the lower one-third of the esophagus.
  • Among gastric cancers, patients with distal tumours had a significantly better survival rate than patients with proximal tumours.
  • DISCUSSION: The incidences of proximal gastric cancer and esophageal adenocarcinoma are increasing, and their survival patterns are different.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] World J Surg. 2006 Oct;30(10):1864-9 [16983479.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):360-7; discussion 368-9 [11524589.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Am J Med. 2002 Oct 15;113(6):499-505 [12427500.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2070-6 [12775731.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] JAMA. 1988 Mar 18;259(11):1690-4 [3278148.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):642-4 [7860138.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):41-55 [8850434.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56 [9752982.001]
  • [Cites] Surg Oncol. 1997 Dec;6(4):193-200 [9775405.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2271-8 [10070298.001]
  • [Cites] Cancer Invest. 2004;22(6):897-912 [15641488.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] World J Gastroenterol. 2005 Jul 21;11(27):4131-9 [16015679.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Can J Gastroenterol. 2006 Apr;20(4):271-6 [16609756.001]
  • [Cites] Ann Thorac Surg. 2006 Sep;82(3):1073-7 [16928541.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):548-53 [11522738.001]
  • (PMID = 18299732.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2659133
  •  go-up   go-down


50. Shiraishi T, Shimizu I, Horie T, Okazaki M, Teraoka M, Takeichi K, Uehara K, Fujiwara K, Fujiwara S, Yamamoto H, Iuchi A, Wakatsuki S, Ito S: A patient with octopus pot-shaped cardial cancer that metastasized to multiple organs. J Med Invest; 2005 Feb;52(1-2):122-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autopsy revealed a protruding lesion measuring about 3 cm with erosion measuring 5 mm in diameter immediately below the esophago-gastric conjugation site, suggesting primary cardial undifferentiated adenocarcinoma.
  • In the primary focus, changes on the mucosal surface were almost normal However, below the mucosa, infiltration of cancer cells was observed in an approximately 3 cm area along the gastric wall.
  • In our patient, metastatic lesions were detected in multiple organs, including the stomach.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Gastric Mucosa / pathology. Humans. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751284.001).
  • [ISSN] 1343-1420
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Liu JF, Jamieson GG, Wu TC, Zhu GJ, Drew PA: A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol; 2009 May;16(5):1397-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
  • BACKGROUND: We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia.
  • There was a significant improvement in survival for patients with adenocarcinoma of the cardia on aspirin compared with the two control groups combined (P = 0.029).
  • However, there was no significant difference between the survival curves for T2N0M0 adenocarcinoma patients on aspirin (21) and the two control groups combined (65) (P = 0.29).
  • [MeSH-major] Adenocarcinoma / drug therapy. Aspirin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cyclooxygenase 2 Inhibitors / administration & dosage. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cardia. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Analysis


52. Forshaw MJ, Gossage JA, Chrystal K, Cheong K, Atkinson S, Botha A, Harper PG, Mason RC: Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction. Eur J Surg Oncol; 2006 Dec;32(10):1114-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
  • AIMS: To evaluate a single unit's experience with neoadjuvant chemotherapy for treating locally advanced non-metastatic initially resectable and unresectable oesophago-gastric cancer.
  • METHODS: The medical records of all patients with either locally advanced carcinoma of the lower oesophagus or cardia treated with neoadjuvant chemotherapy between August 1999 and January 2003 were reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621430.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  •  go-up   go-down


53. Schröder W, Wirths K, Gutschow C, Vallböhmer D, Bludau M, Schumacher B, Neuhaus H, Hölscher AH: Transthoracic esophagectomy after endoscopic mucosal resection in patients with early esophageal carcinoma. J Gastrointest Surg; 2009 Feb;13(2):223-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Three patients had a squamous cell carcinoma (SCC) and 13 patients an adenocarcinoma (AC), nine patients with a long segment Barrett's esophagus.
  • In two patients, a second carcinoma was detected during histopathologic work-up (1x AC in the cardia and 1x SCC in the cervical esophagus).

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1177-83 [15464466.001]
  • [Cites] Langenbecks Arch Surg. 2006 Sep;391(5):455-60 [16896830.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):962-72; discussion 972-4 [15570202.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):703-10 [15557945.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):365-7 [10430138.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] Jpn J Surg. 1976 Jun;6(2):69-78 [994356.001]
  • [Cites] Virchows Arch. 2005 May;446(5):497-504 [15838647.001]
  • [Cites] Langenbecks Arch Surg. 2006 Aug;391(4):304-21 [16830151.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):114-8 [16330950.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):807-11 [12374665.001]
  • [Cites] Dis Esophagus. 2000;13(2):125-9 [14601903.001]
  • [Cites] Can J Gastroenterol. 1998 Jul-Aug;12(5):355-9 [9773215.001]
  • [Cites] Gut. 2001 Oct;49(4):534-9 [11559651.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Chirurg. 2003 Aug;74(8):726-33 [12928793.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1470-3 [9361616.001]
  • [Cites] Gut. 2004 May;53(5):634-40 [15082579.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):178-86 [8625089.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):776-81 [15326572.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):77-9 [17323470.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1226-32 [15233658.001]
  • [Cites] Endoscopy. 2006 Feb;38(2):149-56 [16479422.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):791-800 [15492560.001]
  • [Cites] World J Surg. 2002 May;26(5):584-7 [12098049.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):483-90 [15024309.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):241-6 [17245177.001]
  • (PMID = 18923875.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Maksimovic S: Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience. Med Arh; 2010;64(2):116-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience.
  • PURPOSE: Gastric cancer (GC) remains one of the most frequent cancers worldwide.
  • The double tract (DT) method is the optimal reconstruction procedure aftertotal gastrectomy for patients with gastric cancer.
  • Tumor diffused in the sections of stomach in 37 cases: cardia and body in 14 cases, body and antrum in 16 cases, and in only body of stomach in 7 cases.
  • In the pathological examination, the tumors of 34 patients were diagnosed as adenocarcinoma, 2 as malignant lymphoma, and i as leiomyosarcoma.
  • [MeSH-major] Digestive System Surgical Procedures. Gastrectomy / rehabilitation. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514781.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


55. Wang DC, Wang LD, Zheng S, Fan ZM, Li JL, Feng CW, Zhang YR, Liu B, Gao SS, He X: [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma].
  • OBJECTIVES: To evaluate the serum biomarkers for diagnosis of gastric cardia dysplasia (DYS) and chronic atrophic gastric-carditis (CAG) and to provide a novel screening method for high risk population of gastric-cardia adenocarcinoma (GCA).
  • A set of spectra derived from analysis of serum from 143 symptom-free subjects at high-risk area for GCA, including 63 cases with histologically normal gastric cardia epithelia, 57 of CAG and 23 of DYS, were analyzed by bioinformatics like decision tree classification algorithm.
  • CONCLUSIONS: The gastric cardia lesions of DYS and CAG could be identified by SELDI-TOF-MS technique specifically in symptom-free subjects at high incidence area for GCA.
  • [MeSH-major] Biomarkers, Tumor / blood. Cardia. Gastritis, Atrophic / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194406.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Lindblad M, García Rodríguez LA, Chandanos E, Lagergren J: Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer; 2006 Jan 16;94(1):136-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.
  • Oesophageal and gastric adenocarcinoma share an unexplained male predominance, which would be explained by the hypothesis that oestrogens are protective in this respect.
  • We carried out a nested case-control study of hormone replacement therapy (HRT) among 299 women with oesophageal cancer, 313 with gastric cancer, and 3191 randomly selected control women, frequency matched by age and calendar year in the General Practitioners Research Database in the United Kingdom.
  • Among 1 619 563 person-years of follow-up, more than 50% reduced risk of gastric adenocarcinoma was found among users of HRT compared to nonusers (odds ratio (OR), 0.48, 95% confidence interval (CI) 0.29-0.79).
  • This inverse association appeared to be stronger for gastric noncardia (OR 0.34, 95% CI 0.14-0.78) and weaker for gastric cardia tumours (OR 0.68, 95% CI 0.23-2.01).
  • There was no association between HRT and oesophageal adenocarcinoma (OR 1.17, 95% CI 0.41-3.32).
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Hormone Replacement Therapy. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] J Chronic Dis. 1980;33(10):595-605 [7410520.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1980 Dec;65(6):1201-7 [7001123.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5181-2 [7139622.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):529-33 [4055127.001]
  • [Cites] BMJ. 1991 Mar 30;302(6779):766-8 [2021768.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):66-9 [2044927.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):259-64 [1467771.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Gut. 1993 Dec;34(12):1672-6 [8282253.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] IARC Sci Publ. 1997;(138):325-9 [9353673.001]
  • [Cites] Br J Clin Pharmacol. 1998 May;45(5):419-25 [9643612.001]
  • [Cites] Surg Today. 1998;28(10):1007-14 [9786571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4886-94 [10499548.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 2):880-8 [10912438.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):341-5 [11487262.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):319-24 [12073050.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1459-61 [12168823.001]
  • [Cites] JAMA. 2002 Aug 21;288(7):872-81 [12186605.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Pharmacotherapy. 2003 May;23(5):686-9 [12741446.001]
  • (PMID = 16404367.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361087
  •  go-up   go-down


57. Schuhmacher C, Novotny A, Ott K, Feith M, Siewert JR: [Lymphadenectomy with tumors of the upper gastrointestinal tract]. Chirurg; 2007 Mar;78(3):203-6, 208-12, 214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Locally advanced Barrett carcinoma is also an indication for classic two-field lymphadenectomy together with abdominothoracic oesophagectomy and creation of a stomach tube with intrathoracic anastomosis.
  • Adenocarcinoma of the cardia and subcardial gastric cancer including the cardia both require lymphadenectomy analogous to that performed in gastric cancer, with special attention paid to the retroperitoneal lymphatic drainage towards the left kidney pedicle.
  • For therapy of gastric cancer, a systematic D2 lymphadenectomy should always be performed.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Lymph Node Excision / methods. Precancerous Conditions / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Cardia / pathology. Cardia / surgery. Esophagectomy / methods. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging. Prognosis. Thoracic Cavity / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Oct;15(4):751-64 [17030271.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Br J Surg. 1998 Jun;85(6):840-4 [9667720.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1576-84 [16317484.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):303-8 [15028313.001]
  • [Cites] Chirurg. 2006 Dec;77(12):1095-103 [17119884.001]
  • [Cites] World J Surg. 2005 Jun;29(6):700-7 [16078126.001]
  • [Cites] Br J Surg. 1989 Sep;76(9):905-8 [2804584.001]
  • [Cites] Surg Technol Int. 2006;15:32-6 [17029158.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] Br J Surg. 2002 May;89(5):604-8 [11972551.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] World J Surg. 2006 Feb;30(2):191-8 [16425071.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):1015-20 [15239237.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):743-52 [11088069.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1441-9 [16871357.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Chirurg. 2005 Jun;76(6):588-94 [15875146.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):483-90 [15024309.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 17333037.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Frey L, Vetter-Kauczok C, Gesierich A, Bröcker EB, Ugurel S: Cutaneous metastases as the first clinical sign of metastatic gastric carcinoma. J Dtsch Dermatol Ges; 2009 Oct;7(10):893-895
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastases as the first clinical sign of metastatic gastric carcinoma.
  • Cutaneous metastases from gastric cancer are uncommon with a frequency of 7 % but can rarely be the presenting sign.
  • Histology showed a metastatic adenocarcinoma.
  • Initial evaluation revealed liver metastases and gastroscopy then identified a tumor involving the distal esophagus and gastric cardia that was diagnosed as a gastric tubular carcinoma.
  • While gastric carcinoma generally metastasizes to the abdominal wall or lymph nodes, our patient showed an exceptional variant with distant cutaneous metastases as the first clinical sign.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Scalp / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538484.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Carneiro F, Chaves P: Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction. Surg Oncol Clin N Am; 2006 Oct;15(4):697-714
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction.
  • Available evidence supports the existence of two major pathways of neoplastic development in the gastroesophageal region: the Barrett pathway, related to gastroesophageal reflux disease, and the gastric pathway, related to Helicobacter pylori infection.
  • The existence of an independent junctional pathway is questionable, and gastroesophageal junction adenocarcinomas share features of esophageal and gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030268.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 120
  •  go-up   go-down


60. von Rahden BH, Langner C, Brücher BL, Stein HJ, Sarbia M: No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog; 2006 May;45(5):349-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr Virus (EBV) infection is considered to play an etiologic role in human malignancies, including a subset of gastric and cardiac cancers.
  • A surgical series of 82 primary resected gastric (n=36) or cardiac (n=46) adenocarcinomas (TU Munich) was used as control group.
  • None of the 56 small bowel carcinomas exhibited EBER expression whereas in the control group the rate of EBER expression accounted for 4.4% in the group of cardia carcinomas and 8.6% in the group of gastric cancers.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Intestinal Neoplasms / virology. Intestine, Small / virology. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16493667.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


61. Rutegård M, Shore R, Lu Y, Lagergren P, Lindblad M: Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer; 2010 Apr;46(6):1093-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006.
  • BACKGROUND: Oesophageal and gastric adenocarcinoma share a male predominance not seen for other adenocarcinomas of the gastrointestinal tract.
  • METHODS: The Swedish Cancer Register was used to collect primary oesophageal, gastric cardia, non-cardia gastric, colonic and pancreatic adenocarcinoma cases aged 25-84, during the study period of 1970-2006.
  • RESULTS: The sex ratio for oesophageal adenocarcinoma ranged from approximately 10:1 to 4:1, presenting a seemingly consistent decline with age.
  • The sex ratio for non-cardia gastric adenocarcinoma, however, increased with age to reach 2:1 at a point one to two decades after menopause, where the ratio levelled off and eventually declined.
  • There was no discernible time period effect concerning any type of adenocarcinoma.
  • The ratios for gastric cardia, colonic and pancreatic adenocarcinoma were stable with age.
  • CONCLUSION: This study indicates separate patterns of age-dependency of the sex difference in oesophageal and non-cardia gastric adenocarcinoma incidence.
  • The non-cardia gastric adenocarcinoma pattern might be due to a protective effect during premenopausal years for the female population, while the seemingly steady decline in sex ratio in oesophageal adenocarcinoma indicates a mechanism independent of menopause.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology. Esophageal Neoplasms / epidemiology. Pancreatic Neoplasms / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cardia. Female. Humans. Incidence. Male. Middle Aged. Sex Distribution. Sweden / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20188539.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


62. van Duin M, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, Siersema PD, van Dekken H: High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res; 2007;118(2-4):130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 37 specimens, 21 originated from the esophagus and 16 were derived from the gastric cardia.
  • Quantitative RT-PCR analysis of these seven genes was subsequently performed on a panel of 24 gastroesophageal samples, including 13 cell lines, two xenografts and nine normal stomach controls.
  • Significant overexpression was found for MYC and EXT1 in GEJ adenocarcinoma cell lines and xenografts compared to normal controls.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Esophageal Neoplasms / genetics. Esophagogastric Junction / pathology. Nucleic Acid Conformation. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000363.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


63. Rosivatz E, Becker KF, Kremmer E, Schott C, Blechschmidt K, Höfler H, Sarbia M: Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch; 2006 Mar;448(3):277-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequently, a series of 340 adenocarcinomas of the upper gastrointestinal tract, including tumours from the oesophagus (n=154), cardia (n=102) and stomach (n=84), arranged in tissue microarrays, were examined for Snail expression and were correlated to E-cadherin expression and clinico-pathological parameters.
  • Nuclear Snail immunoreactivity was seen in 27 tumours (7.9%) and tended to be more frequent in oesophageal adenocarcinomas (11.1%) than in cardiac (6.9%) or gastric (3.6%) carcinomas (p=0.0428).
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Nucleus / metabolism. Gastrointestinal Neoplasms / metabolism. Transcription Factors / metabolism. Upper Gastrointestinal Tract / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Acta Anat (Basel). 1995;154(1):8-20 [8714286.001]
  • [Cites] Cell. 1991 Jul 12;66(1):107-19 [2070412.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2657-64 [12855644.001]
  • [Cites] Genes Dev. 2004 Jan 1;18(1):99-115 [14701881.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24661-6 [11323412.001]
  • [Cites] Genomics. 1999 Nov 15;62(1):42-9 [10585766.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):465-75 [15297939.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1861-72 [9412478.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1959-67 [12668723.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Cell. 2003 Apr 18;113(2):207-19 [12705869.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):98-101 [11857019.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):543-52 [15679052.001]
  • [Cites] Genetics. 1984 Oct;108(2):347-60 [17246230.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10 ):931-40 [15448698.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):711-9 [15252840.001]
  • [Cites] Nat Med. 2004 Sep;10 (9):917-9 [15322538.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27424-31 [11309385.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Biochim Biophys Acta. 1994 May 27;1198(1):11-26 [8199193.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1919-25 [8934538.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5154-61 [15289319.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1525-8 [11313896.001]
  • [Cites] Nat Cell Biol. 2002 Mar;4(3):222-31 [11836526.001]
  • [Cites] Oncogene. 2004 Sep 23;23 (44):7345-54 [15286702.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39209-16 [12161443.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66 [11994736.001]
  • [Cites] Cell. 2003 Feb 21;112(4):535-48 [12600316.001]
  • [Cites] Virology. 1995 Apr 1;208(1):336-42 [11831716.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):499-511 [12508111.001]
  • [Cites] Am J Pathol. 1991 Jul;139(1):17-23 [1713020.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23 (14 ):5078-89 [12832491.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):365-70 [11756660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61 [11526241.001]
  • [Cites] Genes Dev. 2004 May 15;18(10 ):1131-43 [15155580.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1803-9 [10595908.001]
  • (PMID = 16328348.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger; 0 / Snai2 protein, rat; 0 / Snail Family Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


64. Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, Palli D, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Binghan S, Caldas C, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Rinaldi S, Ferrari P, Riboli E, González CA: Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol; 2008 Nov;19(11):1894-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST).
  • BACKGROUND: The relative contribution to gastric cancer (GC) risk of variants in genes that determine the inflammatory response remains mostly unknown and results from genotyping studies are inconsistent.
  • PATIENTS AND METHODS: A nested case-control study within the prospective European Prospective Investigation into Cancer and Nutrition cohort was carried out, including 248 gastric adenocarcinomas and 770 matched controls.
  • RESULTS: IL1RN 2R/2R genotype [odds ratio (OR) 2.43; 95% confidence interval (CI) 1.19-4.96] and allele IL1RN Ex5-35C were associated with an increased risk of Hp(+) non-cardia GC.
  • IL8 -251AA genotype was associated with a decreased risk of Hp(+) non-cardia GC (OR 0.51; 95% CI 0.32-0.81), mainly of the intestinal type.
  • A moderately increased risk of Hp(+) non-cardia GC for IL4R -29429T variant was observed (OR 1.74; 95% CI 1.15-2.63).
  • CONCLUSION: This prospective study confirms the association of IL1RN polymorphisms with the risk of non-cardia GC and indicates that IL8 -251T>A may modify the risk for GC.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628242.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukins; 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


65. Trivers KF, De Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF, Chow WH: Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol; 2005 Mar;3(3):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers.
  • BACKGROUND AND AIMS: Risk factors for subtypes of esophageal and gastric cancer recently have been identified, but their effect on survival is unknown.
  • Cox regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for esophageal and gastric cancer in relation to prediagnostic factors.
  • RESULTS: Relative to distant stage, esophageal adenocarcinoma (EA) patients with localized disease had a decreased risk for death (HR, .22; 95% CI, .15-.31), followed by those with regional spread (HR, .32; 95% CI, .23-.45).
  • Except for other (non-cardia) gastric adenocarcinomas (OGA), higher household income (> or =15,000 US dollars/y vs. <15,000 US dollars/y) was associated with a 33%-38% decrease in risk for death.
  • CONCLUSIONS: Predictors of lengthened esophageal and gastric cancer survival included higher income (except in OGA), overweight (among EA and OGA patients), and female sex (among ES and OGA patients).
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765441.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN05230; United States / NCI NIH HHS / CP / N02-CP40501; United States / NIEHS NIH HHS / ES / P30ES10126; United States / NCI NIH HHS / CA / T32-CA09330; United States / NCI NIH HHS / CA / U01-CA57923; United States / NCI NIH HHS / CA / U01-CA57949; United States / NCI NIH HHS / CA / U01-CA57983
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


66. Wen D, Zhang N, Shan B, Wang S: Helicobacter pylori infection may be implicated in the topography and geographic variation of upper gastrointestinal cancers in the Taihang Mountain high-risk region in northern China. Helicobacter; 2010 Oct;15(5):416-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic infection of the bacterial not only causes distal stomach cancer, but also confers risk to gastric cardia adenocarcinoma.
  • Because H. pylori infection is inversely associated with esophageal adenocarcinoma, globally the infection rate is significantly correlated with the ratio of squamous carcinoma to adenocarcinoma of the esophagus.
  • These agree with the topography of upper gastrointestinal cancer observed in the Taihang Mountain high-risk region where both gastric cardia and non-cardia adenocarcinoma coincide with esophageal squamous cancer, but with almost no distal esophageal adenocarcinoma.
  • Moreover, as altitude increases from plain to mountains, we observed progressively increasing incidence rates of gastric adenocarcinomas in recent years in the region.
  • Because H. pylori infection is a definite carcinogen to gastric adenocarcinoma and is more prevalent in the mountain than in plain areas due to undeveloped living conditions, the observation gives the impression as though H. pylori infection is implicated.
  • RESULTS:   Coincidence of gastric cancer in the region and a progressively increasing rate of the cancer from the plain towards the mountains indicate H. pylori infection may be implicated in upper gastrointestinal cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / microbiology. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / microbiology. Helicobacter Infections / complications. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21083747.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. van Vliet EP, Steyerberg EW, Eijkemans MJ, Kuipers EJ, Siersema PD: Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis. Br J Cancer; 2007 Oct 8;97(7):868-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis.
  • Computed tomography (CT) is presently a standard procedure for the detection of distant metastases in patients with oesophageal or gastric cardia cancer.
  • We included 569 oesophageal or gastric cardia cancer patients who had undergone CT neck/thorax/abdomen, ultrasound (US) abdomen, US neck, endoscopic ultrasonography (EUS), and/or chest X-ray for staging.
  • The combination of CT neck/thorax/abdomen and US neck was most cost-effective for the detection of metastases in patients with oesophageal or gastric cardia cancer, whereas the performance of CT only had a lower sensitivity for metastases detection and higher costs.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Cardia / pathology. Esophageal Neoplasms / pathology. Lymph Nodes / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1985 Apr;155(1):171-5 [3975398.001]
  • [Cites] Rays. 2006 Jan-Mar;31(1):9-12 [16999368.001]
  • [Cites] Surgery. 1988 Mar;103(3):344-50 [3344487.001]
  • [Cites] Br J Surg. 1989 Oct;76(10):1036-9 [2532050.001]
  • [Cites] Gastrointest Radiol. 1992 Fall;17(4):305-10 [1426845.001]
  • [Cites] Br J Radiol. 1993 Mar;66(783):203-8 [8472112.001]
  • [Cites] Am J Surg. 1993 May;165(5):558-60 [8488936.001]
  • [Cites] Ann Thorac Surg. 1994 May;57(5):1180-3 [8179382.001]
  • [Cites] J Surg Oncol. 1996 Mar;61(3):214-7 [8637210.001]
  • [Cites] Eur J Cancer. 1996 May;32A(5):893-5 [9081373.001]
  • [Cites] Abdom Imaging. 1997 Mar-Apr;22(2):138-42 [9013521.001]
  • [Cites] Chest. 1998 Mar;113(3):687-95 [9515844.001]
  • [Cites] Br J Surg. 1998 Jul;85(7):994-8 [9692582.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):62-6 [9923801.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):20-9 [9934727.001]
  • [Cites] Clin Radiol. 2000 Sep;55(9):696-701 [10988048.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):751-7 [11375583.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):520-30; discussion 530-1 [11573045.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):714-9 [11726846.001]
  • [Cites] Surg Oncol. 2001 Nov;10(3):103-11 [11750229.001]
  • [Cites] Ann Thorac Surg. 2002 Mar;73(3):916-20; discussion 920-1 [11899201.001]
  • [Cites] Psychol Methods. 2002 Jun;7(2):147-77 [12090408.001]
  • [Cites] Ann Thorac Surg. 2002 Oct;74(4):1026-32 [12400740.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1105-12 [12917769.001]
  • [Cites] AJR Am J Roentgenol. 1983 Nov;141(5):951-8 [6605068.001]
  • [Cites] Ann Thorac Surg. 1999 Feb;67(2):319-21; discussion 322 [10197647.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):352-6 [10462655.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4483-9 [16002838.001]
  • [Cites] Abdom Imaging. 2006 Jan-Feb;31(1):25-35 [16333707.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):234-42 [16454824.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):938-47 [16733107.001]
  • [Cites] J Clin Ultrasound. 1985 Mar-Apr;13(3):153-60 [3920276.001]
  • (PMID = 17848957.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360396
  •  go-up   go-down


68. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K, Coebergh JW: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer; 2010 Apr;46(6):1101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.
  • BACKGROUND: Survival of gastric cancer in the Western world remains poor.
  • We conducted a retrospective population-based study to evaluate trends in incidence, treatment and outcome of gastric adenocarcinoma.
  • METHODS: All patients diagnosed with gastric adenocarcinoma during 1990-2007 in the Dutch Eindhoven Cancer Registry area were included (n=4,797).
  • Trend analyses were conducted for incidence, mortality, tumour and patient characteristics, treatment and crude overall survival, according to tumour location (cardia versus non-cardia).
  • The proportion of cardia tumours remained stable.
  • Stage distribution worsened over time among patients with cardia (stages I and II: 32% in 1990-1993 and 22% in 2006-2007, p=0.005) and non-cardia (stage IV: 33% in 1990-1993 and 40% in 2006-2007, p=0.0003) cancer.
  • Five-year survival worsened over time for patients with non-cardia tumours.
  • After adjustments for relevant factors (i.e. stage), the risk of death decreased since the late 90s for patients with a cardia tumour (hazard ratio 0.8, p=0.01).
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms
  • [MeSH-minor] Aged. Cardia. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219351.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


69. Corley DA, Kubo A, Zhao W: Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev; 2008 Feb;17(2):352-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal obesity and the risk of esophageal and gastric cardia carcinomas.
  • BACKGROUND: Esophageal adenocarcinoma is rapidly increasing in incidence.
  • METHODS: Nested case-control study within 206,974 members of the Kaiser Permanente multiphasic health checkup cohort; subjects received detailed questionnaires, a standardized examination including BMI and anthropometric measurements, and follow-up of esophageal and cardia cancers using registry data.
  • RESULTS: 101 incident esophageal adenocarcinomas, 105 cardia adenocarcinomas, and 144 esophageal squamous cell carcinomas were detected (BMI data available for all cases; abdominal measurements for a subset).
  • Increasing abdominal diameter was strongly associated with an increased risk of esophageal adenocarcinoma [odds ratio (OR), 3.47; 95% confidence interval (95% CI), 1.29-9.33; abdominal diameter, > or =25 versus <20 cm].
  • Abdominal diameter was not associated with the risk of cardia adenocarcinomas (OR, 1.28; 95% CI, 0.38-4.25; diameter, > or =25 versus <20 cm) or esophageal squamous cell carcinomas (OR, 0.78; 95% CI, 0.32-1.92).
  • CONCLUSIONS: Increasing abdominal diameter was associated with an increased risk of esophageal adenocarcinoma, independent of BMI.
  • Given abdominal obesity is more common among males, these findings suggest that increases in obesity may disproportionately increase the risk of esophageal adenocarcinoma in males.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Obes Relat Metab Disord. 1998 Apr;22(4):338-42 [9578239.001]
  • [Cites] J Pediatr. 1998 Feb;132(2):211-22 [9506630.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Ann Epidemiol. 1999 Oct;9(7):424-35 [10501410.001]
  • [Cites] Obes Surg. 2005 Oct;15(9):1225-32 [16259876.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 23;345(1):271-9 [16678125.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):887-91 [16803686.001]
  • [Cites] Gut. 2007 Jun;56(6):756-62 [17047097.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):403-11 [17681161.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] FASEB J. 2000 Nov;14(14):2329-38 [11053255.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1014-8 [11529823.001]
  • [Cites] Obes Rev. 2002 Feb;3(1):5-8 [12119660.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Oct;16(10):1795-800 [12269973.001]
  • [Cites] Obes Res. 2003 Oct;11(10):1223-31 [14569048.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1692-9 [15188164.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] Arch Intern Med. 1969 Jun;123(6):664-81 [5771054.001]
  • [Cites] Am J Epidemiol. 1972 Jul;96(1):23-35 [5039726.001]
  • [Cites] Prev Med. 1973 Jun;2(2):197-206 [4723635.001]
  • [Cites] Prev Med. 1973 Jun;2(2):207-20 [4723637.001]
  • [Cites] Prev Med. 1973 Jun;2(2):221-35 [4723638.001]
  • [Cites] Kidney Int. 1982 Jul;22(1):63-8 [6181284.001]
  • [Cites] J Clin Epidemiol. 1988;41(5):427-34 [3367172.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] JAMA. 1995 Oct 4;274(13):1037-42 [7563454.001]
  • [Cites] Scand J Gastroenterol Suppl. 1995;211:7-18 [8545632.001]
  • [Cites] Eur J Cancer Prev. 1996 Dec;5 Suppl 2:57-65 [9061296.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • (PMID = 18268119.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK63616; United States / NIDDK NIH HHS / DK / DK063616-05; United States / NIDDK NIH HHS / DK / K08 DK002697; United States / NIDDK NIH HHS / DK / R01 DK063616; United States / NIDDK NIH HHS / DK / R01 DK063616-05; United States / NIDDK NIH HHS / DK / DK002697-05; United States / NIDDK NIH HHS / DK / KO8 DK02697; United States / NIDDK NIH HHS / DK / K08 DK002697-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS99907; NLM/ PMC2670999
  •  go-up   go-down


71. Wilkinson NW, Howe J, Gay G, Patel-Parekh L, Scott-Conner C, Donohue J: Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation. Ann Surg Oncol; 2008 Jun;15(6):1644-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation.
  • BACKGROUND: While the overall incidence of gastric cancer has declined in the United States of America, the incidence of proximal gastric cancers has increased.
  • The purpose of this analysis was to highlight key differences between proximal and distal gastric cancer as they relate to presentation and treatment.
  • METHODS: Data on 6,099 patients diagnosed with gastric adenocarcinoma were collected as a patient care evaluation under the auspices of the American College of Surgeons Commission on Cancer.
  • RESULTS: The proximal cancer group included 1,924 patients (87% cardia, 13% fundus) and the distal cancer group included 1,311 patients (85% antrum, 15% pylorus).
  • Proportionately, proximal cancer cases were male (P < 0.01), younger (P < 0.01), and White (P < 0.01); whereas, distal gastric cancer cases were Black (P < 0.01), Hispanic (P < 0.01), and Asian (P = 0.01).
  • CONCLUSIONS: The populations that developed proximal verses distal gastric cancer differed with respect to sex, age, and racial background.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392661.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Madani K, Zhao R, Lim HJ, Casson AG: Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg; 2010 Jun;37(6):1427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study.
  • OBJECTIVE: This study evaluates the clinical significance of p53 mutations in oesophageal adenocarcinoma (EADC).
  • Strict clinicopathologic criteria were used to define primary EADC (Type I), excluding gastric cardia adenocarcinoma (Type II).
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Genes, p53. Mutation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20227286.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


73. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


74. Wu MH, Lin MT, Lee PH: Clinicopathological study of gastric metastases. World J Surg; 2007 Jan;31(1):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of gastric metastases.
  • OBJECTIVE: The stomach is an uncommon site for metastasis, and most of the reported examples would appear to have been caused by direct invasion from primary malignancies.
  • Metastases to the stomach are extremely rare, and few cases have been reported in the literature.
  • This study was intended to evaluate the character of and the prognosis for metastasized tumors of the stomach.
  • METHOD: We evaluated the medical records of patients who had presented at the National Taiwan University Hospital over a period of 10 years prior to writing who had malignancies and had developed metastasis to the stomach.
  • RESULT: From October 1995 to October 2004 inclusively, only 18 patients featuring known malignancies with metastases to the stomach were found.
  • The site of the metastasis was the gastric body for 9 patients, the gastric antrum for 6, the cardia or fundus for 2, and the entire stomach for 1.
  • The time period elapsing between the emergence of the primary malignancy and the gastric metastasis was less than 2 years for 3 patients and about 5-6 years for another 2 patients.
  • The mean time elapsing from the diagnosis of gastric metastasis to patient death was quite short, namely, about 6 months.
  • CONCLUSION: Carcinomas featuring gastric metastasis are typically very rare and reveal a rather poor prognosis.
  • [MeSH-major] Stomach Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / secondary. Female. Gastrectomy. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2006;9(1):19-25 [16557432.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1596-600 [2311070.001]
  • [Cites] J Clin Gastroenterol. 1981;3 Suppl 1:35-7 [7328295.001]
  • [Cites] Can J Surg. 1962 Oct;5:438-41 [13954414.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):209-12 [15770407.001]
  • [Cites] Am J Surg. 1960 Jan;99:94-6 [13814449.001]
  • [Cites] Eur J Radiol. 1983 Nov;3(4):331-8 [6653567.001]
  • [Cites] J Gastroenterol Hepatol. 2000 May;15(5):536-41 [10847441.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):311-8 [12229937.001]
  • [Cites] Radiol Clin North Am. 1993 Nov;31(6):1359-73 [8210355.001]
  • (PMID = 17186432.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Li YM, Zhu SC, Liu ZK, Song CL, Wang YX, Wang SJ: [Characteristics of the lymph node metastases and influencing factors and their value in target region delineation in postoperative radiotherapy for thoracic esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 May;32(5):391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The metastatic lymph nodes of upper-thoracic esophagus were mainly observed in the supraclavicular and paratracheal regions (P < 0.05), the metastatic lymph nodes of middle-third thoracic esophagus were bidirectional, and those of the lower-third thoracic esophagus mainly metastasized to the regions adjacent to the esophagus, gastric cardia and gastric artery (P < 0.05).
  • Both the metastasis ratio and rate of lymph nodes adjacent to the gastric artery in the lower-thoracic esophageal cancer were significantly higher than those in the middle-third and upper-third thoracic esophageal cancers (P = 0.007, P = 0.001).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Irradiation. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neovascularization, Pathologic / pathology. Retrospective Studies. Small Cell Lung Carcinoma / pathology. Small Cell Lung Carcinoma / radiotherapy. Small Cell Lung Carcinoma / surgery. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723441.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


76. Dong XJ, Wang N, Guo W, Zhou RM, Zhang XJ, Li Y: [Correlations of XRCC5 polymorphisms to genetic susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a high incidence region]. Ai Zheng; 2007 Mar;26(3):280-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of XRCC5 polymorphisms to genetic susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a high incidence region].
  • This study was to investigate the correlations of XRCC5 polymorphisms to genetic susceptibility to esophageal squamous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA) in a population of high incidence region, Cixian and Shexian counties of Hebei Province, China.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. DNA Helicases / genetics. Esophageal Neoplasms / genetics. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics
  • [MeSH-minor] Alleles. Cardia / pathology. China / epidemiology. Confidence Intervals. DNA Repair. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Odds Ratio. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Smoking


77. Zheng B, Chen YB, Hu Y, Wang JY, Zhou ZW, Fu JH: [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia]. Chin J Cancer; 2010 Jan;29(1):94-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia].
  • BACKGROUND AND OBJECTIVE: The incidence of adenocarcinoma of the cardia has recently increased.
  • This study compared the clinicopathology and prognosis of patients with gastric cardia adenocarcinoma in different periods between 1984 and 2003.
  • METHODS: A total of 589 patients with pathologically confirmed gastric cardia adenocarcinoma hospitalized in Sun Yat-sen University Cancer Center between 1984 and 2003 were divided into 5-year groups.
  • CONCLUSIONS: During the past 20 years, associated with the upward-trending incidence of gastric cardia adenocarcinoma, the admission rate at our hospital of patients with the tumor increased.
  • [MeSH-major] Adenocarcinoma. Cardia / pathology. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038318.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Azagra JS, Ibañez-Aguirre JF, Goergen M, Ceuterick M, Bordas-Rivas JM, Almendral-López ML, Moreno-Elola A, Takieddine M, Guérin E: Long-term results of laparoscopic extended surgery in advanced gastric cancer: a series of 101 patients. Hepatogastroenterology; 2006 Mar-Apr;53(68):304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of laparoscopic extended surgery in advanced gastric cancer: a series of 101 patients.
  • BACKGROUND/AIMS: The objective of our paper is to report on the remote results of patients with gastric cancer treated by mini-invasive surgery as a surgical tool with the "intention to treat with laparoscopy".
  • METHODOLOGY: Between June 1993 and January 2004, 101 patients comprising 72 men and 29 women with gastric adenocarcinoma were prospectively selected by two hospitals based on prior agreement (the CHU Charleroi, Belgium, and Zumárraga Hospital, the Basque Country, Spain).
  • Patients with adenocarcinoma of the cardia were excluded.
  • CONCLUSIONS: Laparoscopic gastrectomy with any kind of lymphadenectomy is a heavy but safe operation, and produces acceptable mortality and morbidity rates in patients with advanced gastric cancer in a general poor condition.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy. Laparoscopy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608045.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


79. Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ: Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol; 2005 Dec 1;92(3):160-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the EGJ can be categorized in two types of cancer divided according to their anatomical origin: distal esophageal adenocarcinoma and adenocarcinoma of the gastric cardia.
  • However, due to their location, in the transitional zone of the esophagus and stomach, there is constant debate about the proper classification, staging, and management of these tumors.
  • The etiology of distal esophageal adenocarcinoma is clearly related to gastroesophageal reflux disease (GERD) and the development of a Barrett's esophagus [2].
  • The etiology of adenocarcinoma of the gastric cardia is less well understood.
  • Special attention will be given to differences and similarities of adenocarcinomas of the gastric cardia and distal esophagus.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms. Esophagogastric Junction. Stomach Neoplasms
  • [MeSH-minor] Barrett Esophagus / complications. Diagnosis, Differential. Diet. Gastric Mucosa / pathology. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Metaplasia. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16299781.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


80. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH: Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia. World J Gastroenterol; 2006 Jun 28;12(24):3883-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia.
  • AIM: To investigate the influence of a positive proximal margin in total gastrectomy patients with gastric adenocarcinoma of the cardia.
  • METHODS: Medical records of 191 patients with total gastrectomies for adenocarcinoma of the cardia between 1995 and 2000 were reviewed.
  • CONCLUSION: A positive margin is more of an indication of advanced disease in patients with gastric adenocarcinoma of the cardia rather than an independent prognostic factor for survival.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cardia / pathology. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1977 Apr;144(4):563-6 [847612.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] Am J Surg. 1980 May;139(5):711-3 [7468923.001]
  • [Cites] Ann Surg. 1982 Dec;196(6):685-90 [7149820.001]
  • [Cites] Aust N Z J Surg. 2000 Oct;70(10):700-3 [11021482.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1773-6 [11037842.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):810-4 [11087650.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):588-93 [12943624.001]
  • [Cites] Curr Probl Surg. 1973 Nov;:3-72 [4592910.001]
  • [Cites] Surg Gynecol Obstet. 1987 Sep;165(3):247-50 [3629439.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1347-51 [3675199.001]
  • [Cites] J Surg Oncol. 1989 Mar;40(3):162-9 [2465454.001]
  • [Cites] Ann Acad Med Singapore. 1989 Jan;18(1):69-71 [2712522.001]
  • [Cites] J Surg Oncol. 1989 Nov;42(3):170-4 [2811381.001]
  • [Cites] Acta Chir Scand. 1990 Feb;156(2):127-30 [2330791.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] J Surg Oncol. 1993 May;53(1):60-3 [8479199.001]
  • [Cites] Br J Surg. 1993 Nov;80(11):1418-20 [8252353.001]
  • [Cites] Am J Surg. 1995 Mar;169(3):316-9 [7879834.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):873-7 [8847038.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):433-7 [8814687.001]
  • [Cites] Aust N Z J Surg. 1996 Nov;66(11):734-7 [8918379.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Br J Surg. 1981 Feb;68(2):73-4 [7459624.001]
  • (PMID = 16804975.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087938
  •  go-up   go-down


81. Le A, Berger D, Lau M, El-Serag HB: Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States. Ann Surg Oncol; 2007 Sep;14(9):2519-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States.
  • BACKGROUND: The overall survival with non-cardia gastric adenocarcinoma in the United States has remained poor and relatively unchanged over the past 2 decades.
  • We examined the trends, extent, and determinants of surgical treatment and the influence of gastrectomy and adequacy of lymphadenectomy (defined as collection of 15 or more lymph nodes) on non-cardia gastric cancer survival.
  • METHODS: Data from Surveillance, Epidemiology, and End Results (SEER) registries was used to identify patients with non-cardia adenocarcinoma diagnosed during 1983-2002.
  • Logistic regression was used to examine determinants of gastric resection and adequacy of lymphadenectomy.
  • RESULTS: There were 16,846 patients with non-cardia gastric cancer of whom 10,534 (62.5%) underwent gastric resection.
  • Resection for non-cardia gastric cancer declined 6% for all stages and 20% for local stages between 1983 and 2002.
  • The mortality risk of surgically treated non-cardia cancer patients has been unchanged for 15 years.
  • CONCLUSION: Gastrectomy for non-cardia gastric adenocarcinoma is underutilized, especially for localized disease.
  • In the majority of operations for non-cardia gastric cancer, LN collection is inadequate.
  • Racial and geographic variations with gastric resection and LN sampling are as significant as patient age and stage of the cancer.
  • Disparities based on race and geographic region, as well as surgeon and facility factors need to be investigated and addressed to bring forth improvements in outcomes for non-cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Lymph Node Excision / methods. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610016.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA: Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut; 2007 Nov;56(11):1503-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study.
  • BACKGROUND: In the last decades, the incidence of oesophageal and gastric cardia adenocarcinoma has increased rapidly in the Western world.
  • We investigated the association between body mass index (BMI), height and risk of oesophageal and gastric cardia adenocarcinoma.
  • After 13.3 years of follow-up, excluding the first follow-up year, complete data from 4552 subcohort members, 133 oesophageal and 163 gastric cardia adenocarcinomas were available for case-cohort analyses.
  • RESULTS: The RRs (95% CI) of oesophageal adenocarcinoma were 1.40 (0.95 to 2.04) and 3.96 (2.27 to 6.88) for overweight (BMI 25.0-29.9 kg/m(2)) and obese subjects (BMI >or=30.0 kg/m(2)), respectively, compared to subjects with normal weight (BMI 20.0-24.9 kg/m(2)).
  • For gastric cardia adenocarcinoma, these RRs were 1.32 (0.94 to 1.85) and 2.73 (1.56 to 4.79).
  • Also change in BMI during adulthood was positively associated with the risk of oesophageal and gastric cardia adenocarcinoma (p trend 0.001 and 0.02, respectively), while no association was found with BMI in early adulthood (p trend 0.17 and 0.17, respectively).
  • CONCLUSIONS: These results confirm higher risks of oesophageal and gastric cardia adenocarcinoma with increasing BMI.
  • This implies that the increasing prevalence of obesity may be one of the explanations for the rising incidence of oesophageal and gastric cardia adenocarcinoma in the Western world.
  • [MeSH-major] Adenocarcinoma / etiology. Body Height / physiology. Cardia. Esophageal Neoplasms / etiology. Obesity / complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):975-9 [11521805.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22 [11981334.001]
  • [Cites] Int J Obes Relat Metab Disord. 2002 Sep;26(9):1218-24 [12187399.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):269-70 [12397649.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):66-72 [12837713.001]
  • [Cites] Int J Epidemiol. 2003 Aug;32(4):645-50 [12913045.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):940-8 [12942560.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] Am J Clin Nutr. 1981 Aug;34(8):1593-9 [7270483.001]
  • [Cites] Am J Epidemiol. 1982 Feb;115(2):223-30 [7058781.001]
  • [Cites] J Clin Epidemiol. 1990;43(3):285-95 [2313318.001]
  • [Cites] Int J Epidemiol. 1990 Sep;19(3):553-8 [2262247.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Epidemiology. 1990 Mar;1(2):146-52 [2073502.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):369-77 [9149898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):481-5 [9232333.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Eur J Cancer Prev. 1999 Apr;8(2):115-22 [10335457.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1167-75 [15561645.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [CommentIn] Gut. 2007 Nov;56(11):1493-4 [17938426.001]
  • (PMID = 17337464.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2095659
  •  go-up   go-down


83. Wijetunge S, Ma Y, DeMeester S, Hagen J, DeMeester T, Chandrasoma P: Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction," and "gastric cardia" with gastric pathology. Am J Surg Pathol; 2010 Oct;34(10):1521-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction," and "gastric cardia" with gastric pathology.
  • Controversy exists as to whether adenocarcinomas occurring in the gastroesophageal junctional region and gastric cardia originate in the esophagus or the stomach.
  • Esophageal adenocarcinoma is known to be strongly associated with gastroesophageal reflux disease; gastric adenocarcinoma with Helicobacter pylori gastritis, and gastric intestinal metaplasia.
  • This study evaluates the association of these tumors with pathologic findings in the biopsies of the gastric body and the antrum.
  • It is hypothesized that if these malignancies are esophageal, they should have little or no significant association with gastric pathology; if they are gastric, these patients should have a high prevalence of gastric pathology.
  • Between 2004 and 2008, 234 patients were diagnosed with high-grade dysplasia (HGD) and/or adenocarcinoma; 107 were distal esophageal, 79 straddled the distal end of the tubular esophagus, and 48 were in the "gastric cardia."
  • Gastric biopsies were assessed for inflammation, H. pylori infection, and intestinal metaplasia.
  • During this period, 2146 patients had nonmalignant columnar epithelia in the esophagus with similar assessment of the stomach; these acted as a control group.
  • The gastric biopsy was normal in 201/234 (85.9%) patients and showed significant inflammation, H. pylori infection, and/or gastric intestinal metaplasia in 33/234 (14.1%) patients.
  • There was no gastritis, H. pylori infection, or intestinal metaplasia in 88/107 (82.2%) of the patients with distal esophageal HGD and/or adenocarcinoma, 70/79 (88.6%) with junctional HGD and/or adenocarcinoma, and 43/48 (85.9%) with "gastric cardiac" HGD and/or adenocarcinoma.
  • The incidence of gastritis was significantly higher in the patients with HGD and/or adenocarcinoma (33/234 or 14.1%) than in the control population (146/2146 or 9.0%; P=0.01).
  • This difference was largely the result of a higher incidence of gastritis in patients with HGD and/or adenocarcinoma in the distal third of the esophagus (19/107 or 17.8%) versus the control population (146/2146 or 9.0%; P=0.01).
  • The incidence of H. pylori positivity was also significantly higher in the patients with HGD and/or adenocarcinoma in the distal third of the esophagus (13/107 or 12.2%) than in the control population (117/2146 or 5.5%; P=0.01).
  • There was no significant difference between the control group and the patients with junctional and gastric cardiac HGD and/or adenocarcinoma for gastritis, H. pylori infection, or the gastric intestinal metaplasia.
  • The absence of gastritis, H. pylori, and the gastric intestinal metaplasia in 85.9% of the patients with HGD and/or adenocarcinoma of the gastroesophageal junctional region strongly suggest that most of these originate in the esophagus.
  • In the small minority of patients whose HGD and/or adenocarcinoma were associated with gastric pathology, the incidence of gastritis and H. pylori infection was significantly higher in patients with HGD and/or adenocarcinoma in the distal third of the esophagus and not in the junctional and "gastric cardiac" tumors.
  • This suggests that the reflux of the gastric juice whose composition has been altered by gastritis and H. pylori infection may be associated with an increased tendency to HGD and/or adenocarcinoma in the distal third of the esophagus.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophagogastric Junction / pathology. Stomach / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871225.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z: Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res; 2009 Sep 28;14(10):453-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma.
  • The aim of this study was to investigate the promoter methylation and expression of E-cadherin gene in gastric cardiac adenocarcinoma (GCA).
  • CONCLUSIONS: High methylation status of the 5' CpG island of E-cadherin gene may be one of the mechanisms in the development of gastric cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Cardia. CpG Islands. DNA Methylation. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):869-76 [10023662.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Lancet. 1999 Jul 31;354(9176):356-7 [10437861.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(4):1-17 [14987388.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):376-9 [7841055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):355-9 [9139867.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • (PMID = 19748854.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3352230
  •  go-up   go-down


85. Bafandeh Y, Hashemzadeh S, Sokouti M, Esmaili H: Clinicopathologic characteristics of esophageal cancer patients in northwest Iran--very low incidence of adenocarcinomas. Asian Pac J Cancer Prev; 2006 Jul-Sep;7(3):480-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have recently shown that the incidence of Barrett's esophagus, a precancerous lesion for esophageal adenocarcinoma (AC) is very low in the northwest of the country.
  • We localized the tumors in esophagus and esophago-gastric junction.
  • Type III gastric cardial cancers were excluded.
  • However, distinct esophageal adenocarcinomas was only seen in two and in the remainder gastric cardia was also involved.
  • SCC was more frequent in females, and adenocarcinoma in males (x 2=8.89, df=2, p=0.012.
  • CONCLUSION: In this Iranian population, the incidence of esophageal adenocarcinoma is very much lower than in Western countries.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Barrett Esophagus / epidemiology. Barrett Esophagus / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Cardia / pathology. Esophagogastric Junction / pathology. Female. Humans. Incidence. Iran / epidemiology. Male. Middle Aged. Prospective Studies. Retrospective Studies. Risk Factors. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology. Western World

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059350.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


86. Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS: Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol; 2009 Mar;24(3):354-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis.
  • There is conflicting data regarding the clinicopathological significance of the risk factors associated with Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC).
  • EBVaGC developed most often in the cardia and body, and it generally showed the diffuse histological type.
  • The clinicopathological and molecular characteristics of EBVaGC are quite different from those of conventional gastric adenocarcinoma.
  • [MeSH-major] Carcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335785.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 75
  •  go-up   go-down


87. Wang Y, Guo W, He Y, Chen Z, Wen D, Zhang X, Wang N, Li Y, Ge H, Zhang J: Association of MTHFR C677T and SHMT(1) C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Causes Control; 2007 Mar;18(2):143-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the association between the C to T transition in the methylenetetrahydro folate reductase gene (MTHFR C677T) and the C to T transition in the serine hydroxymethyltransferase ( 1 )gene (SHMT ( 1 ) C1420T) and the increased risk of carcinogenesis of esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA) in a population of high incident region of Northern China.
  • [MeSH-major] Adenocarcinoma / genetics. Cardia. Esophageal Neoplasms / genetics. Glycine Hydroxymethyltransferase / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Neoplasms, Squamous Cell / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206530.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.2.1 / Glycine Hydroxymethyltransferase
  •  go-up   go-down


88. Bai JG, Lv Y, Dang CX: Adenocarcinoma of the Esophagogastric Junction in China according to Siewert's classification. Jpn J Clin Oncol; 2006 Jun;36(6):364-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the Esophagogastric Junction in China according to Siewert's classification.
  • BACKGROUND: There had never been a clear definition of the cancer of cardia before Siewert's classification, which was proposed in 1996 and approved in 1997 at the second International Gastric Cancer Congress in Munich.
  • On the basis of the classification, this study aims to research into the clinicopathological characteristics and surgical modes of adenocarcinoma of the esophagogastric junction in China.
  • METHODS: The study reviewed the data of the distal esophageal cancer, the cancer of cardia and the proximal gastric cancer at the First Hospital of Xi'an Jiaotong University from January 1995 to December 1999.
  • RESULTS: Among the 203 patients, there were 29 patients with adenocarcinoma of the distal esophagus (Type I); 80 patients with true carcinoma of cardia (Type II); and 94 patients with subcardial carcinoma (Type III).
  • [MeSH-major] Adenocarcinoma / classification. Esophageal Neoplasms / classification. Esophagectomy. Esophagogastric Junction. Lymph Node Excision. Stomach Neoplasms / classification
  • [MeSH-minor] Barrett Esophagus / pathology. Cardia. China / epidemiology. Female. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymph Nodes / pathology. Male. Metaplasia. Middle Aged. Morbidity. Postoperative Complications / etiology. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766566.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A: A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer; 2008 Feb;44(3):465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma (EADC) is rapidly increasing in Western countries and obesity is thought to be a major risk factor.
  • We examined the association between BMI and EADC, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in a cohort of approximately 500,000 people in the United States (US).
  • We found that compared to people with a BMI of 18.5-25kg/m2, a BMI > or = 35 was associated with significantly increased risk of EADC, HR (95% CI)=2.27 (1.44-3.59) and gastric cardia adenocarcinoma 2.46 (1.60-3.80), but not gastric non-cardia adenocarcinoma 0.84 (0.50-1.42).
  • [MeSH-major] Adenocarcinoma / etiology. Attitude to Health. Body Mass Index. Cardia. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):319-23 [3856045.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):481-5 [9232333.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • (PMID = 18221867.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS42480; NLM/ PMC2350215
  •  go-up   go-down


90. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR: Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol; 2008 May;3(5):516-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
  • PURPOSE: This study was undertaken to explore the response rate of a first-line, three-drug regimen that consisted of bortezomib, paclitaxel, and carboplatin in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2006 Aug;59(2):128-38 [16829119.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2546-8 [15958811.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88 [9427274.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):960-5 [15151955.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Nov;126(5):1603-8 [14666040.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(2):207-15 [16763792.001]
  • [Cites] Anticancer Drugs. 2007 Jul;18(6):677-86 [17762396.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4647-51 [17671158.001]
  • (PMID = 18449005.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA035267; United States / NCI NIH HHS / CA / U10 CA037417; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA035269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / U10 CA060276; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA-52654; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / U10 CA063849; United States / NCI NIH HHS / CA / CA-35119; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / N01 CA015083; United States / NCI NIH HHS / CA / U10 CA035103
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS547678; NLM/ PMC3929582
  •  go-up   go-down


91. Mattioli S, Ruffato A, Di Simone MP, Corti B, D'Errico A, Lugaresi ML, Mattioli B, D'Ovidio F: Immunopathological patterns of the stomach in adenocarcinoma of the esophagus, cardia, and gastric antrum: gastric profiles in Siewert type I and II tumors. Ann Thorac Surg; 2007 May;83(5):1814-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunopathological patterns of the stomach in adenocarcinoma of the esophagus, cardia, and gastric antrum: gastric profiles in Siewert type I and II tumors.
  • BACKGROUND: The morphologic and immunohistochemical profiles of gastric mucosa and of the tumor were assessed in Siewert type I, type II, and gastric antrum adenocarcinomas.
  • METHODS: Sixty-two patients, prospectively operated upon, were included in the study: 37 type II, 15 type I, and 10 antrum adenocarcinoma.
  • Samples of the tumor, the surrounding area, and the gastric corpus and antrum were analyzed histologically, and immunostained for cytokeratins (CK)7/20 (staining positive for cells labeled > or = 50%).
  • (1) 13 of 37 (35%) had intestinal metaplasia (IM) in the stomach;.
  • (5) 100% showed the same CK immunoprofile, both in IM and adenocarcinoma (measure of agreement k = 1, p = 0.000).
  • (2) 100% gastric samples devoid of both IM and HP infection.
  • One hundred percent of antrum adenocarcinomas showed a no Barrett's type CK profile, both in the tumor and in the IM of the entire stomach.
  • CONCLUSIONS: Data suggest that type II adenocarcinoma cannot be always considered a gastroesophageal reflux disease-related tumor; other pathogenetic pathways should be taken into consideration.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Stomach / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barrett Esophagus / pathology. Cardia / pathology. Esophagogastric Junction / pathology. Female. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Pyloric Antrum / pathology


92. Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z, Kuang G: Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol; 2010;2010:721485
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma.
  • AIM: Investigate the promoter methylation of the Thrombospondin-1 (TSP1) gene in gastric cardia adenocarcinoma (GCA).
  • [MeSH-major] Adenocarcinoma / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics. Thrombospondin 1 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2003 Jan 15;116(Pt 2):217-24 [12482908.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):509-19 [11980922.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6299-310 [14559817.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):245-58 [15036264.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):961-8 [15094109.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Jan;68(1):240-3 [5276296.001]
  • [Cites] Blood. 1985 Jan;65(1):79-84 [3965054.001]
  • [Cites] J Cell Biol. 1985 Sep;101(3):1059-70 [4030891.001]
  • [Cites] J Cell Biol. 1989 Feb;108(2):719-27 [2493001.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):755-61 [2714880.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2899-903 [8428963.001]
  • [Cites] J Cell Biol. 1993 Aug;122(4):923-32 [8349738.001]
  • [Cites] Int J Cancer. 1994 Oct 15;59(2):191-5 [7927918.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] J Cell Sci. 1995 Feb;108 ( Pt 2):797-809 [7539439.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1183-91 [8751720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1793-801 [9528751.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):733-40 [16075282.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):3534-41 [16951312.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3112-20 [16835379.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5930-9 [17442977.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):14-21 [18425817.001]
  • [Cites] Cell. 2008 Aug 8;134(3):392-404 [18692464.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7090-9 [18757424.001]
  • [Cites] Curr Drug Targets. 2008 Oct;9(10):842-50 [18855618.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):2947-54 [10706681.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):597-614 [11102749.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2427-36 [11160302.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Oncology. 2003;64(4):423-9 [12759541.001]
  • (PMID = 20300551.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thrombospondin 1
  • [Other-IDs] NLM/ PMC2838370
  •  go-up   go-down


93. Wang LD, Qin YR, Fan ZM, Kwong D, Guan XY, Tsao GS, Sham J, Li JL, Feng XS: Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China. Dis Esophagus; 2006;19(6):459-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China.
  • In China, gastric cardia adenocarcinoma (GCA) shares very similar geographic distribution with SCC, suggesting the possibility of similar risk factors involved in SCC and GCA carcinogenesis in these areas.
  • However, the underlying genetic alterations for esophageal and gastric cardia carcinogenesis, especially for the molecular difference between SCC and GCA, are largely unknown.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069589.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR: Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol; 2007 Apr;14(4):1312-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spleen preservation in radical surgery for gastric cardia cancer.
  • BACKGROUND: In gastric cardia cancer (GCC), the spleen is usually removed when the tumor is resected.
  • The purpose of this study was to investigate the effect of spleen preservation on survival following radical resection for gastric cardia cancer.
  • CONCLUSIONS: Splenectomy does not improve survival of patients who undergo curative resection for gastric cardia cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Spleen / physiology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265118.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Moenig SP, Luebke T, Baldus SE, Schroeder W, Bollschweiler E, Schneider PM, Hoelscher AH: Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases. Anticancer Res; 2005 Mar-Apr;25(2B):1349-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases.
  • BACKGROUND: The feasibility and diagnostic reliability of sentinel lymph node biopsy of gastric carcinoma are still unclear and controversial.
  • PATIENTS AND METHODS: To assess the applicability of the sentinel node concept to gastric carcinoma, we retrospectively analyzed the location of metastatic lymph nodes in patients with only one or two lymph node metastases.
  • RESULTS: A total of 135 patients, who underwent gastrectomy with D2 lymphadenectomy for primary gastric adenocarcinoma between 1997 and 2001, were enrolled in this study.
  • Skip metastases were only seen in one patient with cardia carcinoma and lymph node involvement of compartment II (left gastric artery).
  • CONCLUSION: In patients with gastric carcinoma, especially in early stage carcinoma, the phenomenon of skip metastasis is infrequent.
  • Therefore, the sentinel node concept may be feasible in gastric cancer.
  • [MeSH-major] Sentinel Lymph Node Biopsy. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865090.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


96. Ohdaira H, Noro T, Terada H, Kameyama J, Ohara T, Yoshino K, Kitajima M, Suzuki Y: New double-stapling technique for esophagojejunostomy and esophagogastrostomy in gastric cancer surgery, using a peroral intraluminal approach with a digital stapling system. Gastric Cancer; 2009;12(2):101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New double-stapling technique for esophagojejunostomy and esophagogastrostomy in gastric cancer surgery, using a peroral intraluminal approach with a digital stapling system.
  • In the abdominal-transhiatal approach for resection of adenocarcinoma of the cardia or subcardia, and in laparoscopy-assisted total gastrectomy (LATG), the use of a circular stapling device has potential problems with the placement of the purse-string suture and insertion of the anvil of the instrument.
  • [MeSH-major] Digestive System Surgical Procedures / instrumentation. Digestive System Surgical Procedures / methods. Stomach Neoplasms / surgery. Surgical Stapling / instrumentation. Surgical Stapling / methods
  • [MeSH-minor] Anastomosis, Surgical / instrumentation. Anastomosis, Surgical / methods. Esophagus / surgery. Humans. Stomach / surgery. Surgical Staplers. Sutures

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2001;4(2):98-102 [11706768.001]
  • [Cites] Surg Clin North Am. 1989 Dec;69(6):1227-36 [2512659.001]
  • [Cites] Gastric Cancer. 2007;10(3):176-80 [17922096.001]
  • [Cites] Surg Technol Int. 2005;14:113-7 [16525962.001]
  • [Cites] Obes Surg. 2003 Dec;13(6):837-41 [14738666.001]
  • [Cites] Gastric Cancer. 2007;10(3):181-6 [17922097.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):50-2 [2405935.001]
  • [Cites] Gastric Cancer. 1999 Dec;2(4):230-234 [11957104.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):127-9 [9354169.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2004 Aug;14(4):230-3 [15472555.001]
  • [Cites] Am J Surg. 2002 Jul;184(1):58-60 [12135722.001]
  • [Cites] Am J Surg. 1997 Jul;174(1):61-2 [9240954.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):174-6 [11574091.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1166-74 [16055298.001]
  • [Cites] Br J Surg. 1989 Sep;76(9):909-12 [2804585.001]
  • [Cites] Obes Surg. 2003 Feb;13(1):88-94 [12630620.001]
  • (PMID = 19562464.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Ye W, Kumar R, Bacova G, Lagergren J, Hemminki K, Nyrén O: The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis; 2006 Sep;27(9):1835-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden.
  • Mechanisms behind the strong associations of esophageal adenocarcinoma risk with gastroesophageal reflux (GOR) and body mass remain to be defined.
  • In a nationwide population-based case-control study, we examined associations of polymorphisms in the DNA repair genes XPD, XPC, XRCC1 and XRCC3 with risk of esophageal adenocarcinoma, squamous-cell carcinoma (SCC) and gastric cardia adenocarcinoma, and paid special attention to possible interactions with symptomatic reflux or body mass.
  • We collected blood samples from 96, 81 and 126 interviewed incident cases of esophageal adenocarcinoma, esophageal SCC and gastric cardia adenocarcinoma, respectively, and 472 randomly selected controls, frequency-matched with regard to age and sex.
  • XPD codon 751 Lys/Gln and Gln/Gln genotypes, compared with Lys/Lys genotype, were both associated with a more than doubled risk for esophageal adenocarcinoma (OR=2.4; 95% CI=1.4-4.4; OR=2.7, 95% CI=1.3-5.9).
  • Our study suggests that XPD 751Gln allele is a potential genetic marker for susceptibility to esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Xeroderma Pigmentosum Group D Protein / genetics. Xeroderma Pigmentosum Group D Protein / physiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / genetics. Case-Control Studies. Female. Humans. Male. Middle Aged. Polymorphism, Genetic. Risk. Stomach Neoplasms / genetics. Sweden

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571649.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA57947-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


98. Zhang XF, Wang YM, Ge H, Cao YY, Chen ZF, Wen DG, Guo W, Wang N, Li Y, Zhang JH: Association of CDH1 single nucleotide polymorphisms with susceptibility to esophageal squamous cell carcinomas and gastric cardia carcinomas. Dis Esophagus; 2008;21(1):21-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of CDH1 single nucleotide polymorphisms with susceptibility to esophageal squamous cell carcinomas and gastric cardia carcinomas.
  • To investigate the influence of CDH1 SNP on susceptibility to esophageal squamous cell carcinomas (ESCC) and gastric cardia adenocarcinomas (GCA), a case-control study was conducted among 333 ESCC patients, 239 GCA patients and 343 controls from a northern Chinese population.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197935.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins
  •  go-up   go-down


99. Vial M, Grande L, Pera M: Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:1-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • The incidence of adenocarcinoma of the esophagus and esophagogastric junction (gastric cardia) has risen rapidly over the past three decades in the United States and northern Europe.
  • However, less than 10% of the patients with esophageal adenocarcinoma were known to have Barrett's esophagus before.
  • Current evidence indicates that gastroesophageal reflux and obesity are major risk factors for adenocarcinoma of the esophagus.
  • Abdominal obesity, more prevalent in males, and independent of body mass index, seems to be associated with an increased risk of esophageal adenocarcinoma but not of cardia adenocarcinoma.
  • This observation may explain the high male:female ratio observed in esophageal adenocarcinoma.
  • Tobacco use has also been found as a possible risk factor for adenocarcinoma of the esophagus and gastric cardia.
  • On the other hand, low intake of fruits, vegetables, and cereal fibers seem to increase the risk of esophageal adenocarcinoma.
  • Currently, there is no evidence that strongly supports any specific strategy to screen a subgroup of the population at risk for adenocarcinoma of the esophagus or esophagogastric junction.
  • Future strategies to decrease obesity and tobacco use might help to reduce the burden of esophageal adenocarcinoma at least partially.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology


100. Kim MA, Lee HS, Yang HK, Kim WH: Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer; 2005 Apr 1;103(7):1439-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach.
  • BACKGROUND: Although the incidence <